<<

СПИСОК ЛИТЕРАТУРЫ

1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И. И. Дедов, М. В. Шестакова // Сахарный диабет. -

2011. -№3. -Прил. 1. - С. 4-72.

2.

Аметов, А. С. Уровень гликированного гемоглобина как значимый маркер полноценного гликемического контроля и предиктор поздних сосудистых осложнений сахарного диабета 2 типа / А. С. Аметов // Русский мед. жури. -2011. -Т. 19.-№13.-С. 832-837.

3. Аронов, Д. М. Каскад терапевтических эффектов статинов / Д. М. Аронов // Кардиология. - 2004. - №10. - С. 85-94.

4. Арутюнов, Г. П. Коронарный атеросклероз. Новые данные для нового взгляда на вечную проблему / Г. П. Арутюнов // Сердце. - 2005. - Т. 4. - № 1. - С. 4-10.

5. Ахмедов, В. А. Особенности иммунологических нарушений у больных инфарктом миокарда / В. А. Ахмедов, А. С. Тращенко, Т. Ф. Соколова // Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. - 2009. - Т. 7. - № 3. - С. 46-48.

6. Бобровская, Е. E., Бурова Н. H., Кон, В. Е. Предикторы осложненного течения и неблагоприятного прогноза у больных инфарктом миокарда / Е. Е. Бобровская, Н. Н. Бурова, В. Е. Кон // Артериальная гипертензия. - 2009. - Т. 15. - № 5. - С. 539-542.

7. Влияние инсулинорезистентности и нарушений углеводного обмена на течение острого периода инфаркта миокарда / Л. В. Квиткова, Т. С. Еленская, О. П. Благовещенская и др. // Проблемы эндокринологии. - 2011. - Т. 57. - № 2. -

С. 9-13.

8. Дедов, И. И., Балаболкин, М. И. Инсулиновая резистентность в патогенезе сахарного диабета типа 2 и медикаментозная возможность ее преодоления / И. И. Дедов, М. И. Балаболкин // Врач. - 2006. - № 11. - С. 3-9.

9. Демографический ежегодник России. 2012: стат. сб. // Росстат. -M.-

2012. -535 с.

10. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST: нац. рекомендации / Л.

3. Полонецкий, Л. Г. Гелис, В. П. Подпалов и др. // Кардиоваскулярная терапия и профилактика. - 2007. - Т. 6. - № 8. - Прил. 1 - 66 с.

11. Динамика воспалительного процесса у больных с острым коронарным синдромом и стабильной стенокардией. Сообщение I. Биохимические, иммунологические и клинические аспекты / В. В. Кухарчук, К. А. Зыков, В. П. Масенко и др. // Кардиологический вестник. - 2007. - Т. 2. - С. 3-13.

12. Динамика провоспалительных и противовоспалительных цитокинов у больных с острым инфарктом миокарда / И. М.Фуштеин, С. Л. Подсевахина, О. В. Ткаченко и др. // Запорожская медицинская академия постдипломного образования. Медицина неотложных состояний. - 2010. - № 2. - С. 10-14.

13. Драпкина, О. M., Корнеева, О. H., Шептулина, А. Ф. Статины и сахарный диабет: риск и польза / О. М. Драпкина, О. Н. Корнеева, А. Ф. Шептулина // Кардиоваскулярная терапия и профилактика. - 2012. - № 6. - С. 85- 90.

14. Драпкина, О. M., Костюкевич, М. В. Статины и риск развития сахарного диабета / О. М. Драпкина, М. В. Костюкевич // Сахарный диабет. - 2012.-№2.-С. 77-82.

15. Драпкина, О. M., Смирин, В. И., Ивашкин, В. Т. Инсулинорезистентность и болезни сердца: есть ли связь? / О. М. Драпкина, В. И. Смирин, В. Т. Ивашкин // Фарматека. - 2009. - № 15. - С. 61-65.

16. Еленская, Т. С. Клиническое и прогностическое значение показателей инсулинорезистентности у больных инфарктом миокарда с подъёмом сегмента ST: автореф. дис. канд. мед. наук: 14.01.02, 14.01.05 / Т. С. Еленская // Новосибирск. -2012. -21 с.

17. Значимость факторов риска и сопутствующих заболеваний в течение острого инфаркта миокарда, ассоциированного с артериальной гипертонией / Л. Б.

Ким, Н. Г. Минина, Л. П. Цыба и др. 11 Российский кардиологический журнал. - 2007.-№2(64).-С. 47-51.

18. Инсулин и инсулинорезистентность: новые молекулы-маркеры и молекулы-мишени для диагностики и терапии заболеваний центральной нервной системы / А. Б. Салмина, Н. А. Лузина, Н. В. Кувачева и др. // Бюллетень сибирской медицины.

- 2013. - Т. - 12. - № 5. - С. 104-118.

19. Инсулинорезистентность как ранний предиктор неблагоприятного течения хронической болезни почек недиабетической этиологии (обзор литературы) / Е. И. Леванковская, М. Ю. Швецов, А. В. Зилов и др. // Нефрология и диализ. -2010. -Т. 12. -№2. - С. 74-81.

20. Карпов, Р. С. Коронарная и сердечная недостаточность / под общей редакцией Р. С. Карпова. - Томск: STT, 2005. - 716 с.

21. Карпов, Ю. А. Инфаркт миокарда: на перекрестке мнений. Принципы ведения больных после инфаркта миокарда: профилактика осложнений с первых часов заболевания / Ю. А. Карпов // Consilium medicum. - 2006. - Т. 8. - № 5. - С. 62-65.

22. Климов, А. Н. Атеросклероз. Проблемы патогенеза и терапии / А. Н. Климов. - СПб.: Медицинская литература, 2006. - 246 с.

23. Кляритская, И. Л., Максимова, Е. В. Инсулинорезистентность и гепатит C / И. Л. Кляритская, Е. В. Максимова // Крымский терапевтический журнал. - 2009. - № 2 (13). - С. 32-37.

24. Кобалава, Ж. Д., Толкачева, В. В. Еипергликемия у пациентов с острым коронарным синдромом: современное состояние проблемы. Научные рекомендации Комитета по сахарному диабету Американской ассоциации сердца / Ж. Д. Кобалава, В. В. Толкачева // Кардиология. - 2009. - № 3. - С. 77-85.

25. Кремнева, Л. В., Шалаев, С. В. Еипергликемия у больных острым коронарным синдромом / Л. В. Кремнева, С. В. Шалаев // Атеротромбоз. - 2009. - Т. 2. -№1.-С. 86-94.

26. Майоров, А. Ю. Инсулинорезистентность в патогенезе сахарного диабета 2 типа / А. Ю. Майоров // Сахарный диабет. - 2011. - № 1. - С. 35-43.

27. Малиованова, И. М. Коронарный атеросклероз и статины / И. М. Малиованова // Креативная кардиология. - 2009. - № 2. - С. 118-130.

28. Митченко, Е. И., Романов, В. Ю. Исследование гиполипидемической эффективности, безопасности и влияния на инсулинорезистентность терапии аторвастатином у больных ИБС и сахарным диабетом типа 2 / Е. И. Митченко, В. Ю. Романов // Consilium medicum. - 2010. - Т. 4. - № 5. - С. 12-14.

29.

Мычка, В. Б., Чазова, И. Е. Влияние гиполипидемической терапии на инсулинорезистентность у пациентов с метаболическим синдромом / В. Б. Мычка, И. Е. Чазова// Системные гипертензии. -2004. -№ 1. - С. 16-18.

30. Насонов, Е. Л. Иммунологические маркеры атеросклероза / Е. Л. Насонов // Терапевт, арх. - 2002. -№ 5. - С. 80-85.

31. Насонов, Е. Л. Иммунопатология застойной сердечной недостаточности: роль цитокинов / Е. Л. Насонов // Кардиология. - 1999. - №

3.-Р. 66-73.

32. Насонов, Е. Л. Маркеры воспаления и атеросклероз: значение C- реактивного белка / Е. Л. Насонов // Кардиология. - 1999. - № 2. - С. 81-85.

33. Насонов, Е. Л. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные) / Е. Л. Насонов, Е. В. Патокова, Е. Н. Александрова // Кардиология. - 2001 - № 6. - С. 60-64.

34. Оганов, Р. Г., Концевая, А. В., Калинина, А. М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации / Р. Г. Оганов, А.

В. Концевая, А. М. Калинина // Кардиоваскулярная терапия и профилактика. - 2011.-Т. 10.-№4.-С. 4-9.

35. Оганов, Р. Г., Масленникова, Г. Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения / Р. Г. Оганов, Г. Я. Масленникова / Кардиоваскулярная терапия и профилактика. - 2012. - Т. 11. -№ 1.-С. 5-10.

36. Оганов, Р. Г., Масленникова, Г. Я. Стратегия профилактики сердечнососудистых заболеваний в Российской Федерации / Р. Г. Оганов, Г. Я. Масленникова // Клиническая медицина. - 2012. - Т. 90. - № 3. - С. 4-7.

37. Острый коронарный синдром без подъемов сегмента ST на ЭКГ: разнонаправленные изменения показателей гемостаза при раннем применении аторвастатина и правастатина / Е. В. Покровская, Н. А. Грацианский, О. В. Аверков и др. // Кардиология. - 2003. - № 43. С. 4-13.

38. Ранние липидные и плеотропные эффекты аторвастатина у больных стабильной стенокардией с гиперхолестеринемией / С. В. Краснокутский, Г. И. Кочуев, И. В. Дяченко и др. // Вісник Сумського державного університету.

Сер. Медицина. - 2006. - Т. 86. - № 2. - С. 131-138.

39. Роль инсулинорезистентности в развитии сердечно-сосудистых событий постинфарктного периода / Т. С. Еленская, О. П. Благовещенская, Л. В. Квиткова и др. // Кардиология в Белоруссии. - 2011. - № 5. - С. 104.

40. Сердечно-сосудистые заболевания в Российской Федерации на рубеже веков: смертность, распространенность, факторы риска / Л. А. Бокерия, И. Н. Ступаков, И. В. Самородская и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. - 2007. - Т. 8. - № 5. - С. 5-11.

41. Смоленская, О. Г., Макарова, В. Л., Зенин, Д. М. Развитие коронарного атеросклероза при нарушении углеводного обмена / О. Г. Смоленская, В. Л. Макарова, Д. М. Зенин // Кардиоваскулярная терапия и профилактика. - 2008. - Т. 7. - № 1. - С. 348.

42. Статины и сахарный диабет: цена сотрудничества / А. А. Александров, М. Н. Ядрихинская, С. С. Кухаренко и др. // Сахарный диабет. - 2012. - № 2. С. 70-76.

43. Тканевая инсулинорезистентность: степень выражения и взаимосвязь с факторами риска сердечно-сосудистых заболеваний: [Электронный ресурс] / М. Н. Мамедов, А. М. Олферьев, А. Н. Бриттов и др. // Российский кардиологический журнал. - 2000. - № 1. - URL: http://medi.ru/doc/6600110.htm (09.12.2012).

44. Фомин, В. В., Козловская, Л. В. С-реактивный белок и его значение в кардиологической практике / В. В. Фомин, Л. В. Козловская // Журнал доказательной медицины для практикующих врачей. - 2003. - №5. - P. 70-75.

45. Ханферян, Р. А. Модифицирующее влияние блокатора НЗ/Н4- гистаминовых рецепторов имопроксифана на уровень интерлейкиновой продукции в смешанных лимфоцитарных культурах у больных Q-позитивным инфарктом миокарда / Р. А. Ханферян // Журнал научных публикаций аспирантов и докторантов. - 2007. - №12. - С. 23-27.

46. Хельсинкская декларация Всемирной медицинской ассоциации [Электронный ресурс]: рек. для врачей по проведению биомед. исследований на людях. - URL: http:// doctors.of.lugansk.ua/Publ/Hels_D.html. Хельсинская декларация всемирной медицинской ассоциации (12.07.2013).

47. Шварц, В. Значение постпрандиальной гипергликемии в развитии сердечно-сосудистых заболеваний при сахарном диабете 2 типа / В. Шварц // Клин, медицина. - 2009. -№ 11. - С. 17-24.

48. Шестакова, М. В. Сахарный диабет и ишемическая болезнь сердца: влияние инсулинорезистентности и её коррекции на сердечно-сосудистый прогноз / М. В. Шестакова // Болезни сердца и сосудов. - 2006. - Т. 2. - № 2. -

С. 35-42.

49. Яковенко, Е. И. Влияние метаболических эффектов статинов на клинические проявления атеросклероза / Е. И. Яковенко, М. Н. Мамедов // Российский кардиолог, жури. - 2012. - Т. 2. - № 94. - С. 85-90.

50. Янчитайтите, JI., Растяните, Д. Прогноз у больных, перенесших инфаркт миокарда с зубцом Q нижней или передней локализации / Л. Янчитайтите, Д. Растяните // Кардиология. - 2007. - № 8. - С. 36-39.

51. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A / R. Kawaguchi, J. Yu, J. Honda et al. // Science. - 2007. - Vol. 315. - P. 820-825.

52. A novel serum protein similar to Clq produced exclusively in adipocytes / P. E. Sherer, S. Williams, M. Fogliano et al. // J Biol Chem. - 1995. - Vol. 270. - P. 26746-26749.

53. A rho-associated protein kinase, ROK-alpha, binds insulin receptor substrate-1 and modulates insulin signaling / S. Farah, Y. Agazie, N. Ohan et al. // J. Biol. Chem. - 1998. - Vol. 273. -P. 4740-4746.

54. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis / S. Verma, С. H. Wang, S. H. Li et al. // Circulation. - 2002. - Vol. 106 (8). -P. 913-919.

55. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine / J. L. Anderson, C. D. Adams, E. M. Antman et al. // Circulation. - 2007. - Vol. 116. - P. el48-e304.

56. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centres / С. B. Lawrence, A. C. Snape, F. M. Baudoin et al. // Endocrinology. -2002. - Vol. 143. -P. 155-162.

57. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates / К. E. Foster-Schubert, J. Overduin, С. E. Prudom et al. // Journal of Clinical Endocrinology and Metabolism. - 2008. - Vol. 93. - P. 1971-1979.

58. Adam, C. L., Findlay, P. A., Miller, D. W. Blood-brain leptin transport and appetite and reproductive. Neuroendocrine responses to intracerebroventricular leptin injection in sheep: influence of photoperiod / C. L. Adam, P. A. Findlay, D. W. Miller // Endocrinology. - 2006. - Vol. 147 (10). - P. 4589-4598.

59. Adipocyte-derived plasma protein, adiponectin acts as a platelet-derived growth factor-88-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell / Y. Arita, S. Kihara, N. Oucta et al. // Circulation. - 2002. - Vol. 105 (25). - P. 2893-2898.

60. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes / M. von Eynatten, J. G. Schneider, S. Hadziselimovic et al. // Diabetes Care. - 2005. - Vol. 28 (3). - P. 754-755.

61. Adipokines and insulin resistance / K. Rabe, M. Lehrke, K. G. Parhofer et al.//Mol. Med. -2008. - Vol. 14 (11-12).-P. 741-751.

62. Adipokines and risk of type 2 diabetes in older men / S. G. Wannamethee, G. D. Lowe, A. Rumley et al. // Diabetes Care. - 2007. - Vol. 30 (5). - P. 1200-1205.

63. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome / T. Kadowaki, T. Yamauchi, N. Kubota et al. // J. Clin. Invest. - 2006. - Vol. 116 (7). - P. 1784-1792.

64. Adiponectin and protection against type 2 diabetes mellitus / J. Spranger,

A. Kroke, M. Mohlig et al. // Lancet. - 2003. - Vol. 361 (9353). - P. 226-228.

65. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study / В. B. Duncan, M. I. Schmidt, J. S. Pankow et al. // Diabetes. - 2004. - Vol. 53 (9). - P. 2473-2478.

66. Adiponectin levels and risk of type 2 diabetes: a systematic reviewand meta-analysis / S. Li, H. J. Shin, E. L. Ding et al. // JAMA. - 2009. - Vol. 302. - P. 179-188.

67. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase / T. Yamauchi, J. Kamon, Y. Minokoshi et al. // Nat. Med. - 2002. - Vol. 8 (11). - P. 1288-1295.

68. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease / C. Zoccali, F. Mallamaci, G. Tripepi et al. // J. Am. Soc. Nephrol. - 2002. - Vol. 13. -P. 134-141.

69. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers / D. Rothenbacher, H. Hermann Brenner, W. Winfried Marz et al. // Eur. Heart J. - 2005. - Vol. 26. - P. 1640-1646.

70. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro / J. P. Bastard, M. Maachi, J. T. Van Nhieu et al. // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87 (5). - P. 2084-2089.

71. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production / M. W. Rajala, S. Obici, P. E. Scherer et al. // J. Clin. Invest. - 2003. - Vol. 111 (2). - P. 225-230.

72. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events / P.M. Ridker, N. Rifai, M. Clearfield et al. // N. Engl. J. Med. - 2001. - Vol. 344 (26). - P. 1959-1965.

73. Alessi, M. PAI-I and the metabolic syndrome: links, causes and consequences / M. Alessi, I. Juhan-Vague // Arterioscler. Thromb. Vase. Biol. - 2006. - Vol. 26 (10). -P. 2200-2207.

74. Ancestral effect on HOMA-IR levels quantitated in an American population of Mexican origin / H. Q. Qu, Q. Li, Y. Lu et al. // Diabetes Care. - 2012. - Vol. 35 (12).-P. 2591-2593.

75. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study / M. Hanefeld, N. Marx, A. Pfutzner et al. // J. Am. Coll. Cardiol. - 2007. - Vol. 49 (3). - P. 290-297.

76. Anti-tumor necrosis factor-a blockade improves insulin resistance in patients with rheumatoid arthritis / M. A. Gonzalez-Gay, J. M. De Matias, C. Gonzalez- Juanatey et al. // Clinical and Experimental Rheumatology. - 2006. - Vol. 24. - P. 83- 86.

77. Apo B/apo A-I ratio is better than LDL-C in detecting cardiovascular risk / G. P. Camevale Schianca, R. Pedrazzoli, S. Onolfo et al. // Nutr. Metab. Cardiovasc. Dis. -2011. - Vol. 21 (6). -P. 406-411.

78. Apo-B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel / P. J. Barter, C. M. Ballantyne, R. Carmena et al. // J. Intern. Med. - 2006. - Vol. 259 (3). - P. 247-258.

79. Amer, P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones / P. Amer // Trends in Endocrinology and Metabolism. - 2003. -Vol. 14 (3).-P. 137-145.

80. Association between high sensitivity C-reactive protein levels in serum and the 5-year-accumulative-risk of diabetes / H. H. Liu, D. Zhao, W. Wang et al. // Zhonghua Liu Xing Bing Xue Za Zhi. - 2011. - Vol. 32 (I). - P. 1-4.

81. Association between non-high density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatoiy Risk in Communities Study (CIRCS) / A. Kitamura, H. Noda, M. Nakamura et al. // J. Atheroscler. Thromb. - 2011. - Vol. 18 (6). - P. 454-463.

82. Association between semm C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction / T. Anzai, T. Yoshikawa, H. Kaneko et al. // Chest. - 2004. - Vol. 125 (2). - P. 384-389.

83. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men / A. Stancakova, T. Kuulasmaa, J. Paananen et al. // Diabetes. - 2009. - Vol. 58. - P. 2129-2136.

84. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies / J. Danesh, R. Collins, P. Appleby et al. // JAMA. - 1998. - Vol. 279. -P. 1477-1482.

85. Association of hemoglobin Alc with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk / K. T. Khaw,

N. Wareham, S. Bingham et al. // Ann. Intern. Med. - 2004. - Vol. 141. - P. 413-420.

86. Association of hypoadiponectinemia with coronary heart diseases in men / M. Kumada, S. Kihara, S. Sumitsuji et al. // Arterioscler. Thromb. Vase. Biol. - 2003. - Vol. 23(1).-P. 85-89.

87. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoom Study / M. B. Snijder, R. J. Heine, J. C. Seidell et al. // Diabetes Care. - 2006 - Vol. 29 (11). - P. 2498-2503.

88. Associations of adiponectin, resistin, and tumor necrosis factor-a with insulin resistance / M. F. Hivert, L. M. Sullivan, C. S. Fox et al. // Journal of Clinical Endocrinology and Metabolism. - 2008. - Vol. 93. - P. 3165-3172.

89. ASTEROID Investigators. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. / S. E. Nissen , S. J. Nicholls, I. Sipahi et al. // JAMA. - 2006. - Vol. 295 (13). - P. 1556-1565.

90. Athyros, V. G., Mikhailidis, D. P. Pharmacotherapy: statins and newonset diabetes mellitus—a matter for debate / V. G. Athyros, D. P. Mikhailidis // Nat. Rev. Endocrinol. -2012. - Vol. 8. -P. 133-134.

91. Atkinson L. L., Fischer M.A., Lopaschuk G.D. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl- CoA carboxylase-malonyl-CoA axis // J. Biol. Chem. - 2002. - Vol. 277. - P. 29424- 29430.

92. Atorvastatin but not pitavastatin significantly increases fasting plasma glucose in patients with type 2 diabetes and combined dyslipidemia (abstract) / V. Kryzhanovski, J. Gumprecht, B. Zhu et al. // J. Am. Coll. Cardiol. - 2011. - Vol. 57. - P. E575.

93. Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients / K. K. Koh, M. J. Quon, S. H. Han et al. // JACC. - 2010.-Vol. 55.-P. 134-139.

94. Atorvastatin decreases the coenzyme QlO level in the blood of patients at risk for cardiovascular disease and stroke / T. Rundek, A. Naini, R. Sacco et al. // Arch. Neurol. - 2004. - Vol. 61. - P. 889-892.

95. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes / C. H. Chu, J. K. Lee, H. C. Lam et al. // J Endocrinol Invest. - 2008. - Vol. 31. - P. 42-47.

96. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats / V. Wong, L. Stavar, L. Szeto et al. // Atherosclerosis. - 2006. - Vol. 184. - P. 348-355.

97. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A / R. Rodriguez-Calvo, E. Barroso, L. Serrano, T. Coll et al. // Hepatology. - 2009. - Vol. 49 (I). - P. 106-115.

98. Augmented expression of cardiotrophin-1 and its receptor component, gpl30, in both left and right ventricles after myocardial infarction in the rat / T. Aoyama, Y. Takimoto, D. Pennica et al. // J Mol Cell Cardiol. 2000. - Vol. 32. - P. 1821-1830.

99. Avogaro, A. Insulin resistance: trigger or concomitant factor in the metabolic syndrome / A. Avogaro // Panminerva Med. - 2006. - Vol. 48. - № I. - P. 3- 12.

100. Baud, V., Karin, M. Signal transduction by tumor necrosis factor and its relatives / V. Baud, M. Karin // Trends in Cell Biology. - 2001. - Vol. 11. - P. 372-377.

101. Beltowski, J. Leptin and atherosclerosis / J. Beltowski // Atherosclerosis. -

2006. - Vol. 189 (I). - P. 47-60.

102. Benefi cial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency / I. S. Farooqi, G. Matarese, G. M. Lord et al. // J. Clin. Invest. - 2002. - Vol. HO. - P. 1093- ПОЗ.

103. Berg, A. H., Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease / A. H. Berg, P. E. Scherer // Circulation Research. - 2005. - Vol. 96.-P. 939-949.

104. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women / B. J. Arsenault, J. S. Rana, E. S. Stroes et al. // J. Am. Coll. Cardiol. - 2009. - Vol. 55 (I). - P. 35-41.

105. Bourcier, T., Libby, P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells / T. Bourcier, P. Libby // Arterioscler Thromb. Vase. Biol. - 2000 - Vol. 20 (2). - P. 556-562.

106. Braunwald, E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials / E. Braunwald // Eur. Heart J. - 2012. - Vol. 33 (4). - P. 430-432.

107. Brown, J. E., Dunmore S. J. Leptin decreases apoptosis and alters BCL-2: Bax ratio in clonal rodentpancreatic beta-cells / J. E. Brown, S. J. Dunmore // Diabetes Metab. Res. Rev. - 2007 - Vol. 23 (6). - P. 497-502.

108. Calabro, P., Willerson, J. T., Yeh, E. T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells / P. Calabro, J. T. Willerson, E. T.Yeh et al. // Circulation. - 2003. -108. - P. - 1930-1932.

109. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions circulation / M. Gwechenberger, L. Mendoza., K. Youker, N. Frangogiannis, C. Smith, L. Michael, M. Entman // Circulation. - 1999. - Vol. 99.-P. 546-551.

HO. Cardiovascular Actions of Insulin / R. Muniyappa, M. Montagnani, К. K. Koh et al. // J. Quon. Endocr. Rev. - 2007. - Vol. 28 (3). - P. 463-491.

111. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial / P. M. Ridker, A. Pradhan, J. G. MacFadyen et al. // Lancet. - 2012. - Vol. 380. - P. 565-571.

112. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range / F. Ning, J. Tuomilehto, K. Pyorala et al. // Diabetes Care. - 2010. - Vol. 33. - P. 2211-2216.

113. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes / D. D. Waters, J. E. Ho, S. M. Boekholdt et al. // J. Am. Coll. Cardiol. - 2013. - Vol. 61. - P. 148-152.

114. Caro, F. Insulin resistance in obese and nonobese man / F. Caro // Clin. Endocrinol. Metab. - 1991. - Vol. 73 (4). -P. 691-695.

115. Case-control analysis of SNPs in GLUT4, RBP4 and STRA6: association of SNPs in STRA6 with type 2 diabetes in a South Indian population / A. K. Nair, D.

Sugunan, H. Kumar et al. // PLoS ONE. - 2010. - Vol. 5. - URL: http://el 1444doi: 10.1371/joumal.pone.OOl 1444.

116. Castelli, W. P. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study / W. P. Castelli // Can. J. Cardiol. - 1988. - Vol. 4. - suppl A. - P. 5A-10A.

117. Cefalu, W. T. Insulin resistance: cellular and clinical concepts / W. T Cefalu // Exp. Biol. Med. - 2001. - Vol. 226. - P. 13-26.

118. Chamberlain, L. H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes / L. H. Chamberlain // FEBS Lett. - 2001. - Vol. 507. - P. 357-361.

119. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice / P. J. Klover, T. A. Zimmers, L. G. Koniaris et al. // Diabetes. - 2003. - Vol. 52 (11). - P. 2794-2890.

120. Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3-L1 adipocytes / A. Xu, L. C. Wong, Y. Wang et al. // FEBS. - 2004. -Vol. 572.-P. 129-134.

121. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes / G. K. Shetty, P. A. Economides, E. S. Horton et al. // Diabetes Care. -

2004. - Vol. 27 (10). -P. 2450-2457.

122. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts / В. H. Chen, Y. Song, E. L. Ding et al. // Diabetes Care. - 2009. - Vol. 32 (2). - P. 329-336.

123. Circulating non-esterified fatty acid level as a predictive risk factor for sudden death in the population / X. Jouven, M. A. Charles, M. Desnos et al. // Circulation. -2001. - Vol. 104 (7). -P. 756-761.

124. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly / E. Ingelsson, J. Sundstrom, H. Melhus et al. // Atherosclerosis. - 2009. - Vol. 206. - P. 239-244.

125. Colbert, J. D., Stone, J. A. Statin use and the risk of incident diabetes mellitus: a review of the literature / J. D. Colbert, J. A. // Stone Can. J. Cardiol. - 2012. - Vol. 28.-P. 581-589.

126. Collet, J. P., Montalescot G., Vicaut E. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality / J. P. Collet, G. Montalescot, E. Vicaut // Circulation. - 2003. - Vol. 108. - P. 391-394.

127. Common variations in the genes encoding C-reactive protein, tumor necrosis factor-а, and interleukin-6, and the risk of clinical diabetes in the Women's Health Initiative Observational Study / K. K. Chan, K. Brennan, N. Y. You et al. // Clin. Chem. -2011. - Vol. 57 (2). -P. 317-325.

128. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) / P. H. Jones, M. H. Davidson, E. A. Stein et al. // Am. J. Cardiol. - 2003. - Vol. 92 (2). - P. 152-160.

129. Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. - 2006. - Vol. 106 (I)-P. 16-20.

130. Correlates of acute insulin resistance in the early phase of non-diabetic ST- elevation myocardial infarction / C. Lazzeri, S. Valente, M. Chiostri et al. // Diabetes and Vascular Disease Research. - 2011. - Vol. 8 (I). - P. 35-42.

131. Correlation analysis of increase in serum level of leptin with that of C reactive protein, troponin T and endothelin in patients with acute myocardial infarction / G. T. Yan, H. Xue, J. Lin et al. // Circulation Research. - 2005. - Vol. 17(9). - P. 2-530.

132. Cowley, M. A. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis / M. A. Cowle // Neuron. - 2003. - Vol. 37. - P. 649-661.

133. C-reactive protein accelerates the progression of atherosclerosis in apohpoprotein E-deficient mice / A. Paul, K. W. Ко, L. Li et al. // Circulation. - 2004. - Vol. 109.-P. 647-655.

134. C-reactive protein and incident cardiovascular events among men with diabetes / M. B. Schulze, E. B. Rimm, T. Li et al. // Diabetes Care. - 2004 - Vol. 27 (4). -P. 889-894.

135. C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients / A. Taniguchi, S. Nagasaka, M. Fukushima et al. // Metabolism. - 2002.-Vol. 51 (12).-P. 1578-1581.

136. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction / T. Anzai, T. Voshikawa, H. Shiraki at al. // Circulation. - 1997. - Vol. 96. - P. 778-784.

137. C-reactive protein attenuates endothelial progenitor cell survival,

differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease / S. Verma, M. A. Kuliszewski, S. H. Li et al. // Circulation. -2004. - Vol. 109 (17). -P. 2058-2067.

138. C-reactive protein augments hypoxia-induced apoptosis through

mitochondrion-dependent pathway in cardiac myocytes / J. Yang, J. Wang, S. Zhu et al. // Mol. Cell. Biochem. - 2008. - Vol. 310 (5). - P. 215-226.

139. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? J. S. Yudkin, C. D. Stehouwer, J. J. Emeis et al. // Arterioscler. Thromb. Vase. Biol. - 1999. - Vol. 19. - P. 972-978. (СРБ предсказывает диабет)

140. C-reactive protein in the arterial intima: role of C-reactive protein receptor- dependent monocyte recruitment in atherogenesis / M. Torzewski, C. Rist, R. F. Mortensen et al. // Arterioscler. Thromb. Vase. Biol. - 2000. - Vol. 20. - P. 2094-2099.

141. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes thereby impairing the insulin signalling pathway that promotes glucose transport / C. D’Alessandris, R. Lauro, I. Presta et al. // Diabetologia. - 2007. - Vol. 50. - P. 840-849.

142. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg

Cohort Study, 1984 to 1992 / W. Koenig, M. Sund, M. Frohlich et al. // Circulation. -

1999. -Vol. 99.-P. 237-242.

143. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study / J. Jeppesen, T. W. Hansen, M. H. Olsen et al. // European Journal of Cardiovascular Prev. Rehabilitation. - 2008. - Vol. 15 (5). - P. 594-598.

144. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus / A. D. Pradhan, J. E. Manson, N. Rifai et al. // JAMA. - 2001. - Vol. 286. - P. 327-334. (CPБ предсказывает диабет)

145. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women / P. M. Ridker, J. E. Birring, N. R. Cook et al. // Circulation. - 2003. - Vol. 107. - P. 391-397.

146. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion / T. Barret, J. Herman, R. Marks et al. // The J. of Pharmacology and experimental therapeutics. - 2002. - Vol. 303 (3). - P.1007-1013.

147. Critical steps in cellular fatty acid uptake and utilization / G. J.Van der Vusse, M. van Bilsen, J. F. Glatz et al. // Mol. Cell. Biochem. - 2002. - Vol. 239. - P. 9-15.

148. DeFronzo, R. A., Tobin, J. D., Andres, R. The glucose clamp technique: a method for quantifying insulin secretion and resistance / R. A. DeFronzo, J. D. Tobin,

R. Andres // Am. J. Physiol. - 1979. - Vol. 6. - P. E214-E223.

149. Devaraj, S. Chan, E., Jialal, I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome / S. Devaraj, E. Chan, I. Jialal // The Journal of Clinical Endocrinology Metabolism. - 2006. - Vol. 91 (I I). - P. 4489-4496.

150. Devaraj, S., Xu, D. Y., Jialal, I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis / S. Devaraj, D. Y. Xu, I. Jialal // Circulation. - 2003. - Vol. 107. - P. 398-404.

151. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins / D. T. Ко, H. C. Wijeysundera, C. A. Jackevicius et al. // Circ. Cardiovasc. QuaL Outcomes. -

2013. - Vol. 6 (3). -P. 315-322.

152. Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program / K. J. Mather, T. Funahashi, Y. Matsuzawa et al // Diabetes. - 2008. - Vol. 57 (4). - P. 980-986.

153. Diagnosing insulin resistance in the general population / K. McAuley, S. Williams, J. Mann et al. // Diabetes Care. - 2001. - Vol. 24. - P. 460-464.

154. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression / E. J. Park, J. H. Lee, G. Y. Yu et al. // Cell. - 2010.-Vol. 140.-P. 197-208.

155. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes / N. V. Chu, A. P. Kong, D. D. Kim et al. // Diabetes Care. - 2002. - Vol. 25. - P. 542-549. (Сахароснижающие препараты эффективно снижают CPБ)

156. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients / K. K. Koh, M. J. Quon, S. H. Han et al. // Atherosclerosis. - 2009. - Vol. 204 (2). - P. 483-490.

157. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance / G. S. Hotamisligil, P. Arner, R. L. Atkinson et al. // Diabetes. - 1997. - Vol. 46. - P. 451-455. ФИО альфа и ИР

158. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis / W. L. Baker, R. Talati, С. M. White et al. // Diabetes Res. Clin. Pract. - 2010. - Vol. 87. - P. 98-107.

159. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake / W. Mauser, N. Perwitz, B. Meier et al. // Eur. J. Pharmacol. - 2007. - Vol. 564.

P. 37-46.

160. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions / D. Kawanami, K. Maemura, N. Takeda et al. // Biochem. Biophys. Res. Commun. - 2004. - Vol. 314 (2). -P.415-419.

161. Disruption of the plasminogen activator inhibitor I gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetes ob/ob mice / K. Schafer, K. Fujisawa, S. Konstantindes et al. // FASEB J. - 2001. - Vol. 15. - P. 1840-1842.

162. Distinct effects of pravastatin, atorvastatin and simvastatin on insulin secretion from a beta-cell line, MIN6 cells / M. Ishikawa, F. Okajima, N. Inoue et al. // J. Atheroscler. Thromb. - 2006. - Vol. 13 (6). - P. 329-335.

163. Disulfide-dependent multimeric assembly of resistin family hormones / S.

D. Patel, M. W. Rajala, L. Rossetti et al. // Science. - 2004. - Vol. 304 (5674). - P. 1154-1158.

164. Dluhy, R. G., McMahon, G. T. Intensive glycemic control in the ACCORD and ADVANCE trials / R. G. Dluhy, G. T. McMahon // N. Engl. J. Med. - 2008. - Vol. 358 (24). - P. 2630-2633. не выявлено преимуществ агрессивного гликемичекого контроля

165. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project / N. Rautio, J. Jokelainen, H. Oksa et al. // BMJ Open. - 2012. - Vol. 2. - P. e001472.

166. Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity / К. H. Kim, L. Zhao, Y. Moon et al. // Proc. Natl. Acad. Sci. U S A. - 2004. - Vol. 101 (17). -P. 6780-6785.

167. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation / C. Tsigos, D. A. Papanicolaou, I. Kyrou et al. // J. Clin. Endocrinol. Metab. - 1997. - Vol. 82 (12). -P. 4167-4170.

168. Dandona, P. Effects of Antidiabetic and Antihyperlipidemic Agents on C- Reactive Protein / P. Dandona // Mayo Clin Proc. - 2008. - Vol. 83 (3). - P. 333-342.

169. Effect of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with MDDM / F. Ofei, S. Hurel, J. Newkirk et al. // Diabetes. - 1996. - Vol. 45. - P. 881-885.

170. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity / D. C. Chan, G. F. Watts, P. H. R. Barrett et al. //Clinical Chemistry. - 2002. - Vol. 48 (6). - P. 877-883.

171. Effect of atorvastatin on hs-CRP in acute coronary syndrome / Gupta A., Dinesh K. Badyal, Prem P. Khosla et al. // British J. Clin. Pharmacol. - 2008. - Vol. 66 (3).-P.411-413.

172. Effect of atorvastatin withdrawal on circulating coenzyme QlO concentration in patients with hypercholesterolemia / C. S. Chu, H. S. Kou, C. J. Lee et al. // Biofactors. - 2006. - Vol. 28. - P. 177-184.

173. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease / G. Marazzi, M. Wajngarten, C. Vitale et al. // Int. J. Cardiol. - 2007. - Vol. 120 (I). - P. 79-84.

174. Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome / F. Fallo, A. Scarda, N. Sonino et al. // Eur. J. Endocrinol. - 2004. -Vol. 150.-P. 339-344.

175. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI- PRO VE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy / С. M. Gibson, Y. B. Pride, C. P. Hochberg et al. // J. Am. Coll. Cardiol. - 2009. - Vol. 54 (24). - P. 2290-2295.

176. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study / J. Shepherd, P. Barter, R. Carmena et al. // Diabetes Care. - 2006. - Vol. 29. - P. 1220-1226.

177. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study) / S. Yusuf, S. Hawken, S. Ounpuu et al. // Lancet. - 2004. - Vol. 364 (9438). - P. 937-952.

178. Effect of pravastatin on the development of diabetes and adiponectin production / T. Takagi, M. Matsuda, M. Abe et al. // Atherosclerosis. - 2008. - Vol. 196. -P. 114-121.

179. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus / S. M. Haffner, A. S. Greenberg, W. M. Weston et al. // Circulation. - 2002. - Vol. 106. - P. 679-684.

180. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin Alc levels in patients with non-ischaemic chronic heart failure / T. Tsutamoto, M. Yamaji, C. Kawahara et al. // Eur. J. Heart. Fail. - 2009. - Vol. 11 (12). - P. 1195-1201.

181. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients / R. Sukhija, S. Prayaga, M. Marashdeh et al. // J. Investig. Med. - 2009. - Vol. 57. -P. 495-499.

182. Effects of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM / F. Ofei, S. Hurel, J. Newkirk et al. // Diabetes. - 1996. - Vol. 45. - P. 881-885.

183. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes / A. Takaguri, K. Satoh, M. Itagaki et al. // J. Pharmacol. Sci. - 2008. - Vol. 107. - P. 80-89.

184. Effects of atorvastatin on apelin, visfatin (nampt), ghrehn and early carotid atherosclerosis in patients with type 2 diabetes / N. P. Kadoglou, N. Sailer, A. Kapelouzou et al. // Acta Diabetol. - 2012. - Vol. 49 (4). - P. 269-276.

185. Effects of free fatty acids on glucose transport and IRS-l-associated phosphatidyl inositol 3-kinase activity / A. Dresner, D. Laurent, M. Marcucci et al. // J. Clin. Invest. - 1999. - Vol. 103 (2). -P. 253-259.

186. Effects of intensive glucose lowering in type 2 diabetes. / H. C. Gerstein, M. E. Miller, R. P. Byington et al. // N. Engl. J. Med. - 2008. - Vol. 358 (24). - P. 2545-2559.

187. Effects of physiologic leptin administration on markers of inflammation, platelet activation and platelet aggregation during caloric deprivation / B. Canavan, R.

O. Salem, S. Schurgin et al. // J. Clin. Endocrinol. Metab. - 2005. - Vol. 90 (10). - P. 5779-5785.

188. Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes / H. Hirose, T. Kawai, Y. Yamamoto et al. // Metabolism. - 2002. - Vol. 51. - P. 314-317.

189. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial /1. Raz, P. W. Wilson, K. Strojek et al. // Diabetes Care. - 2009. - Vol. 32. - P. 381-386.

190. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control / M. Nakata, S. Nagasaka, I. Kusaka et al. // Diabetologia. - 2006. - Vol. 49 (8). - P. 1881-1892.

191. Effects of TNF-a neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome / J. Lo, L. E. Bernstein, B. Canavan et al. // American Journal of Physiology, Endocrinology and Metabolism. - 2007. - Vol. 293. -

P. E102-E109.

192. Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectin / K. Miyagishima, S Hiramitsu, S. Kato et al. // J. Int. Med. Res. - 2007. - Vol. 35 (4). - P. 534-539.

193. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis / P. M. Kearney, L. Blackwell, R. Collins et al. // Lancet. - 2008. - Vol. 371. -P. 117-125.

194. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure / P. A. Kavsak, A. R. MacRae, A. M. Newman et al. // Clin. Biochem. - 2007. - Vol. 40 (5-6). - P. 326-329.

195. Elevated C-reactive protein levels in overweight and obese adults / M. Visser, L. M. Bouter, G. M. McQuillan et al. // JAMA. - 1999. - Vol. 282. - P. 2131- 2135.

196. Elevated levels of acute-phase proteins and plasminogen activator inhibitor I predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study / A. Festa, R. Jr. D’Agostino, R. P. Tracy et al. // Diabetes. - 2002. - Vol. 51 (4). -R 1131-1137.

197. Elevated plasma free fatty acids predict sudden cardiac death: a 6,85-year follow-up of 3315 patients after coronary angiography / S. Pilz, H. Schamagl, B. Tiran et al. // Eur. Heart. J. - 2007. - Vol. 28 (22). - P. 2763-2769.

198. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over I-year follow-up / R. Krecki, M. Krzeminska-Pakula, J. Z. Peruga et al. // Med. Sci. Monit. -2011. - Vol. 17 (I). -P. CR26-CR32.

199. Elevated retinol binding protein-4 levels are associated with metabolic syndrome in Chinese people / Q. Qi, Z. Yu, X. Ye et al. // J. Clin. Endocrin. Metab. -

2007. - Vol. 92. - P. 4827-4834.

200. Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction / M. Sasaki, T. Otani, M. Kawakami et al. // Metabolism. - 2010. - Vol. 59. -P. 527-532.

201. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone / E. Arvat, M. Maccario, L. Di Vitro et al. // J. Clin. Endocrin. Met. - 2001. - Vol. 86. - P. 1169-1174.

202. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial mice infarction / K. M. Kurrelmeyer, L. H. Michael, G. Baumgarten et al. // Proc. Natl. Acad. Sci. USA. -2000. - Vol. 10. -P. 5456-546E

203. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes / A. Fujinami, H. Obayashi, K. Ohta et al. // Clin. Chim. Acta. - 2004. - Vol. 339 (I). - P. 57-63.

204. Ethnic differences in C-reactive protein concentrations / K. A. Hedgepeth,

D. M. Lloyd-Jones, A. Colvin et al. // Clin Chem. - 2008. - Vol. 54. - P. 1027-1037.

205. Evidence for a role of tumor necrosis factor a in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease / S. Jovinge,

A. Hamsten, P. Tomvall et al. // Metabolism. - 1998. - Vol. 47. - P. 113-118.

206. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial mpture and left ventricular dysfunction / M. Sun, F. Dawood, W. H. Wen et al. // Circulation. - 2004. - Vol. 110. - P. 3221-3228.

207. Exogenous ghrelin modulates release of pro-inflammatory cytokones in LPS-stimulated macrophages through distinct signalling pathways / T. Waseem, M. Duxbury, H. Ito et al. // Surgery. - 2008. - Vol. 143. - P. 334-342.

208. Extraadipocyte leptin release in human obesity and its relation to sympathoadrenal function / N. Eikelis, G. Lambert, G. Wiesner et al. // Am. J. Physiol. Endocrinol. Metab. - 2004. - Vol. 286 (5). - P. 744-752.

209. Fantuzzi, G. Adipose tissue, adipokines, and inflammation/ G. Fantuzzi // J. Allergy and Clinical Immunology. - 2006. - Vol. 115 (5). - P. 911-919.

210. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study / J. B. Meigs, D. M. Nathan, R. B. Sr. D’Agostino et al. // Diabetes Care. - 2002. - Vol. 25. - P.1845-1850. Сравнение трех показателей

211. Fasting plasma leptin, tumor necrosis factor- receptor 2, and monocyte chemoattracting protein I concentration in a population of glucose-tolerant and glucose- intolerant women: impact on cardiovascular mortality / L. Piemonti, G. Calori, A. Mercalli et al. // Diabetes Care. - 2003. - Vol. 26 (10). - P. 2883-2889.

212. Feingold, K. R., Gmnfeld, C. Tumor necrosis factor-a stimulates hepatic Hpogenesis in the rat in vivo / K. R. Feingold, C. Gmnfeld // Journal of Clinical Investigation. - 1987. - Vol. 80. -P. 184-190.

213. Fernandes, J., Rilcart, W. Insulin resistance and chronic cardiovascular inflammatory syndrome / J. Fernandes, W. Rilcart // Endocr. Rev. - 2003. - Vol. 24. - P. 278-301.

214. Fernandez-Real, J. M., Moreno, J. M., Ricart, W. Circulating retinolbinding protein-4 concentration might reflect insulin resistance-associated iron overload / J. M. Fernandez-Real, J. M. Moreno, W. Ricart // Diabetes. - 2008. - Vol. 57. - P. 1918-1925.

215. Flachs, P. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet / P. Flachs // Diabetologia. - 2006. - Vol. 49. - P. 394-397.

216. Food fails to suppress ghrelin levels in obese humans / P. J. English, M. A. Ghatei, I. A. Malik et al. // J Clin Endocrin Met. - 2002. - Vol. 87. - P. 2984-2987.

217. Frangogiannis, N. The immune system and cardiac repair / N. Frangogiannis // Pharmacological Research. - 2008. - Vol. 58 (2). - P. 88-111.

218. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy / R. T. de Jongh, E. H. Seme, R. G. Ijzerman et al. // Diabetes. - 2004. - Vol. 53 (I I). - P. 2873- 2882.

219. Fujimaki, S., Kanda, T., Fujita, K. The significance of measuring plasma leptin in acute myocardial infarction / S. Fujimaki, T. Kanda, K. Fujita // J. Int. Med.

Res. -2001. - Vol. 29 (2). -P. 13-108.

220. Gabay, C., Kushner, I. Acute phase proteins and other systemic responses to inflammation / C. Gabay, I. Kushner // N. Engl. J. Med. - 2009. - Vol. 340. - P. 1376-1381.

22 E Generation of C-reactive protein and complement components in atherosclerotic plaques / K. Yasojima, C. Schwab, E. G. McGeer et al. // Am. J. Pathol. -2001. - Vol. 158. -P. 1039-1051.

222. Genetic deletion of IL-6 ameliorates left ventricular dysfunction and remodeling after a reperfused myocardial infarction / H. Taher, Y. Guo, S. K. Sanganalmath et al. // Circulation. - 2008. - Vol. 118. - P. 290.

223. Ghrelin action in brain controls adipocyne metabolism / C. Theander- Carrillo, P. Wiedmer, P. Cettour-Rose et al. // J Clin Invest. - 2006. - Vol. 116. - P. 1983-1993.

224. Ghrelin and leptin: a link between obesity and allergy / K. Matsuda, Y. Nishi, Y. Okamatsu et al. // Journal of allergy and clinical Immunology (St Louis MO). - 2006. - Vol. 117 (3). - P. 705-706.

225. Ghrelin is a growth-hormone-releasing acylated peptide from stomach / M. Kojima, H. Hosoda, Y. Date et al. // Nature. - 1999. - Vol. 402. - P. 656-660.

226. Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential / T. Yada, K. Dezaki, H. Sone et al. // Curr. Diabetes. Rev. - 2008. -Vol. 4. -P. 18-23.

227. Ghrelin response to carbohydrate-enriched breakfast is related to insulin / W. A. Blom, A. Stafleu, C. de Graaf et al. // Am. J. Clin. Nutr. - 2005. - Vol. 81. - P. 367-375.

228. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine and dietary manipulations / H. M. Lee, G. Wang, E. W. Englander et al. // Endocrinology. - 2002. - Vol. 143. -P. 185-190.

229. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans / Y. Date, M. Kojima, H. Hosoda et al. // Endocrinology. - 2000. - Vol. 141. - P. 4255- 4261.

230. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia / R. B. Goldberg, D. M. Kendall, M. A. Deeg et al. // Diabetes Care. - 2005. - Vol. 28. - P. 1547-1554.

231. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe // Lancet. - 1999. - Vol. 354. - P. 617-621.

232. Glucosedependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin / L. O’Rourke, L. M. Gronning, S. J. Yeaman et al. // J. Biol. Chem. - 2002. - Vol. 277 (45). - P. 42557-42562.

233. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults / E. Selvin, M. W. Steffes, H. Zhu et al. // N. Engl. J. Med. - 2010. - Vol. 362. - P. 800-811.

234. Goldfine, A. B. Statins: is it really time to reassess benefits and risks? / A.

B. Goldfme // N. Engl. J. Med. - 2012. - Vol. 366. - P. 1752-1755.

235. Gordon, J. R., Galli, S. J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/ cachectin / J. R. Gordon, S. J. Galli // Nature. - 1990. - Vol. 346. -P. 274-276.

236. Gosman, G. G., Katcher, H. I., Legro, R. S. Obesity and the role of gut and adipose hormones in female reproduction / G. G. Gosman, H. I. Katcher, R. S. Legro // Hum. Reprod. Update. - 2006. - Vol. 12 (5). - P. 585-601.

237. Gould, J. M., Weiser, J. N. Expression of C-reactive protein in the human respiratory tract / J. M. Gould, J. N. Weiser // Infect Immun. - 2001. - Vol. 69. - P.

1747-1754.

238. Haemoglobin Alc levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts / R. Santos-Oliveira, C. Purdy, M. P. da Silva et al. // Diabetologia. - 2011. - Vol. 54. - P. 1327-1334.

239. Hajer, G. R., van Haeften, T. W., Visseren, F. L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases / G. R. Hajer, T. W. van Haeften,

F. L. Visseren // Eur. Heart. J. - 2008. - Vol. 29 (24). - P. 2959-2971.

240. Hansson, G. K. Inflammation, Atherosclerosis, and Coronary Artery Disease / G. K. Hansson // N. Engl. J. Med. - 2005. - Vol. 352. - P. 1685-1690.

241. Hemostasis and fibrinolysis in non-diabetic overweight and obese menand women. Is there still a role for leptin? /1. Mertens, R. V. Considine, M. van der Planken et al. // Eur. J. Endocrinol. - 2006. - Vol. 155 (3). - P. 477-484.

242. High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study / G. Walldius, I. Jungner, I. Holme et al. // Lancet. - 2001. - Vol. 358 (9298). - P. 2026- 2033.

243. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator / V. R. Sopasakis, M. Sandqvist, B. Gustafson et al. // Obes Res. - 2004. - Vol. 12. - P. 454-460.

244. High serum leptin is associated with attenuated coronary vasoreactivity / J. Sundell, R. Huupponen, 0. T. Raitakari et al. // Obes. Res. - 2003. - Vol. 11. - P. 776- 782.

245. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy / M. S. Sabatine, S. D. Wiviott, D. A. Morrow et al. // Circulation. - 2004. - Vol. HO. -P. S834.

246. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial / T. R. Pedersen, 0. Faergeman, J. P. Kastelein et al. // JAMA. - 2005. - Vol. 294 (19). - P. 2437-2445.

247. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study / M .Soinio, J. Mamiemi, M. Laakso et al. // Diabetes Care. - 2006. - Vol. 29 (2). - P. 329-333.

248. Holman, G. D., Kasuga, M. From receptor to transporter: insulin signalling to glucose transport / G. D. Holman, M. Kasuga // Diabetologia. - 1997. - Vol. 40. - P. 1991-1003.

249. HOMA-IR and QUICKI: decide on a general standard instead of making further comparisons / S. M. Rossner, M. Neovius, A. Mattsson et al. // Acta Paediatr. - 2010. - Vol. 99 (I I). - P. 1735-1740.

250. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study / A. J. Hanley, K. Williams, M. P. Stem et al. // Diabetes Care. - 2002. - Vol. 25 (7). - P. 1177-1184.

251. Hotamisligil, G. S., Shargill, N. S., Spiegelman, В. M. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance / G. S. Hotamisligil, N. S. Shargill, В. M. Spiegelman // Science. -1993. - Vol. 259. - P. 87- 91.

252. Hsueh, W. A. Law, R. E. Cardiovascular risk continuum: implications of insulin resistance and diabetes / W. A. Hsueh, R. E. Law // Am. J. Med. - 1998. - Vol. 105 (I).-P. 4-14.

253. Hulten, E., Jackson, J. L., Douglas, K. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome / E. Hulten, J. L. Jackson, K. Douglas // Arch IntemMed. -2006. Vol. 166. -R 1814-1821.

254. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells / A. Abderrahmani, G. Niederhauser, D. Favre et al. // Diabetologia. - 2007. - Vol. 50 (6).-P. 1304-1314.

255. Human leptin enhances activation and proliferation of human circulating T lymphocytes / C. Martin-Romero, J. Santos-Alvarez, R. Gobema et al. // Cell Immunol. -2000.-Vol. 199.-P. 15-24.

256. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease / K. Yasojima, C. Schwab, E. G. McGeer et al. // Brain Res. -

2000. - Vol. 887. -P. 80-89.

257. Human RBP4 adipose tissue expression is gender specific and influenced by leptin / K. Kos, S. Wong, B. Tan et al. // Clinical Endocrinology. - 2010. - Vol. 74. -P. 197-205.

258. Huxley, R., Barzi, F., Woodward, M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 38 prospective cohort studies / R. Huxley, F. Barzi, M. Woodward // B.M.J. - 2006. - Vol. 332. - P. 73-78.

259. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin: potential role in the modulation of its insulin- sensitizing activity / Y. Wang, A. Xu, C. Knight et al. // J. Biol. Chem. - 2002. - Vol. 211.-V. 19521-19529.

260. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population. The Paris Prospective Study, 15-year follow up / A. Fontbonne, M. A. Charles, N. Thibault et al. // Diabetologia. - 1991. - Vol. 34. - P. 356-361.

261. Hyperinsulinemia in patients with coronary heart disease in absence of overt risk factors / C. R. Ariza, A. C. Frati, G. Gomez et al. // Arch. Med. Res. - 1997. - Vol. 28 (I).-P. 115-119.

262. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia / C. Weyer, T. Funahashi, S. Tanaka et al. // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86. - P. 1930-1935.

263. IKK-b links inflammation to obesity-induced insulin resistance / M. C. Arkan, A. L. Hevener, F. R. Greten et al. // Nature Medicine. - 2005. - Vol. 11. - P. 191-198.

264. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and со-regulated acute-phase proteins but not TNF-a or its receptors / S. Muller, S. Martin, W. Koenig et al. // Diabetologia. - 2002. - Vol. 45. -P. 805-812.

265. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis / V. G. Athyros, A. I. Hatzitolios, A. Karagiannis et al. // Arch. Med. Sci. - 2011. - Vol. 7. - P. 984-992.

266. In vivo transfer of soluble TNF-alpha receptor I gene improves cardiac function and reduces infarct size after myocardial infarction in rats / M. Sugano, K. Tsuchida, T. Hata et al. // Faseb. J. - 2004. - Vol. 18. - P. 911-913.

267. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham / W. P. Castelli, R. J. Garrison, P. W. Wilson et al. // JAMA. - 1986. - Vol. 256 (20).-P. 2835-2838.

268. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors / D. Mozaffarian, R. M. Marfisi, G. Levantesi et al. // Lancet. - 2007. - Vol. 370. - P. 667- 675.

269. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals / G. Perseghin,

A. Caumo, М. Caloni et al. // Journal of Clinical Endocrinology and Metabolism. -

2001. - Vol. 86. -P. 4776-4781.

270. Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction / T. Takahashi, T. Anzai, H. Kaneko et al. // Am J. Physiol. Heart. Circ. Physiol. - 2010. - Vol. 299 (6). - P. H1795-H1804.

271. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor / K. K. Wu, T. J. Wu, J. Chin et al. // Atherosclerosis. - 2005. -Vol. 181-P. 251-259.

272. Increased number of islet-associated macrophages in type 2 diabetes / J. A. Ehses, A. Perren, E. Eppler et al. // Diabetes. - 2007 - Vol. 56 (9). - P. 2356-2370.

273. Increased plasma-soluble tumor necrosis factor-а receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects / M. Straczkowski, I. Kowalska, A. Stepien et al. // Diabetes Care. - 2002- Vol. 25. - P. 1824-1828.

274. Increased serum leptin concentrations in patients with chronic stable angina pectoris and ST-elevated myocardial infarction / F. Taneli, S. Yegane, C. Ulman et al. // Angiology. - 2006. - Vol. 57 (3). - P. 267-272.

275. Increased thrombosis after arterial injury in human C-reactive protein- transgenic mice / H. D. Danenberg, A. J. Szalai, R. V. Swaminathan et al. // Circulation. -2003. - Vol. 108. -P. 512-515.

276. Increases in serum unbound free fatty acid levels following coronary angioplasty / A. M. Kleinfeld, D. Prothro, D. L. Brown et al. // Am. J. Cardiol. - 1996. -Vol. 78(12). -P. 1350-1354.

277. Independent association between plasma leptin and C-reactive protein in healthy humans / A. S. Shamsuzzaman, M. Winnicki, R. Wolk et al. // Circulation. - 2004. - Vol. 109. - P. 2181-2185.

278. Induction of adipocyte complement related protein of 30 kilodaltons by PPAR gamma agonists: a potential mechanism of insulin sensitization / T. P. Combs, J. A. Wagner, J. Berger et al. // Endocrinology. - 2002. - Vol. 143. - P. 998-1007.

279. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury / G. L. Kukielka, C. W. Smith, A. M. Manning et al. // Circulation. - 1995. - Vol. 92. - P. 1866-1875.

280. Infection and inflammation-induced proatherogenic changes of lipoproteins / W. Khovidhunkit, R. A. Memon, K. R. Feingold et al. // J. Infect. Dis. - 2000. - Vol. 181 (3). — P. S462-S472.

281. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study / G. Engstom, L. Stavenow, B. Hedblad et al. // Diabetes. - 2003. - Vol. 52 (2). - P. 442-447.

282. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment / B. J. Ansell, M. Navab, S. Hama et al. // Circulation. - 2003. - Vol. 108 (22). - P. 2751-2756.

283. Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion / C. Bickel, H. J. Rupprecht, S. Blankenberg et al. // Int J. Cardiol. - 2002. - Vol. 82 (I). - P. 25-31.

284. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus / T. Yamakawa, T. Takano, S. Tanaka et al. // J. Atheroscler. Thromb. -2008.-Vol. 15.-269-275.

285. Influence of TNF-a and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans / R. Krogh-Madsen, P. Plomgaard, K. Moller et al. // Am. J. Physiol. Endocrinol. Metab. -2006. - Vol. 291 (I). -P. E108-E114.

286. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature / Z. Liu, J. Liu, L. A. Jahn et al. // J. Clin. Endocrinol. Metab. - 2009. - Vol. 94 (9). - P. 3543-3549.

287. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells / T. Yada, M. Nakata, T. Shiraishi et al. // Br. J. Pharmacol. - 1999. - Vol. 126 (5).-P. 1205-1213.

288. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltagegated calcium channel function in pancreatic beta-cells / F. Xia, L. Xie, A. Mihic et al. // Endocrinology. -2008. - Vol. 149. -P. 5136-5145.

289. Inhibition of glucose- and calcium-induced insulin secretion from betaTC3 cells by novel inhibitors of protein isoprenylation / R. Amin, H. Q. Chen, M. Tannous et al. // J. Pharmacol. Exp. Ther. - 2002. - Vol. 303. - P. 82-88.

290. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor / N. Teraoka, M. Mutoh, S. Takasu et al. // Cancer Prev. Res. (Phila). - 2011. - Vol. 4 (3). - P. 445-453.

291. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial / T. J. Orchard, J. Eichner, L. H. Kuller et al. // Ann. Epidemiol. - 1994. - Vol. 4(1).- P. 40-45.

292. Insulin decreases human adiponectin plasma levels / M. Mohlig, U. Wegewitz, M. Osterhoff et al. // Horm Metab Res. - 2002. - Vol. 34. - P. 655-658.

293. Insulin resistance adds prognostic information on long-term clinical outcome after acute myocardial infarction among Japanese patients with and without glucose intolerance / K. Tamita, A. Yamamuro, S. Kaji et al. // Circulation. - 2006. - Vol. 114.-P. 743.

294. Insulin resistance and atherosclerosis / J. Nigro, N. Osman, A. M. Dart et al. // Endocr. Rev. - 2006. - Vol. 27 (3). - P. 242-259.

295. Insulin Resistance Atherosclerosis Study. Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study / A. Festa, R. Jr. D’Agostino, R. P. Tracy etal. //Diabetes. - 2002. - Vol. 51. -P. 1131-1137.

296. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences /1. A. Leclercq, A. Da Silva Morais, B. Schroyen et al. // J. Hepatol. - 2007. - Vol. 47 (I). -P. 142-156.

297. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death / B. Hedblad, P. Nilsson, G. Engstrom et al. // Diabet Med. - 2002. - Vol. 19 (6). - P. 470-475.

298. Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: a prospective follow-up study / M. M. Mikkelsen, T. K. Hansen, J. Gjedsted et al. // J. Cardiothorac. Surg. - 2010. - Vol. 5. - P. 129.

299. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes / A. Patel, S. MacMahon, J. Chalmers et al. // N. Engl. J. Med. - 2008. - Vol. 358 (24).-P. 2560-2572.

300. Intensive lipid lowering with atorvastatin in patients with stable coronary disease / J. La Rosa, S. M. Grundy, D. D. Waters et al. // N. Engl. J. Med. - 2005. - Vol. 352 (14).-P. 1425-1434.

301. Intensive versus moderate lipid lowering with statins after acute coronary syndromes / С. P. Cannon, E. Braunwald, С. H. McCabe et al. // N. Engl. J. Med. - 2004. - Vol. 350 (15). - P. 1495-1504.

302. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction / A. M. Thogersen, S. Soderberg, J. H. Jansson et al. // Eur. J. Cardiovasc. Prev. Rehabil. - 2004. - Vol. 11 (I). - P. 33-40.

303. Interleukin-6 induces cellular insulin resistance in hepatocytes / J. J. Senn, P. J. Klover, I. A. Nowak et al. // Diabetes. - 2002. - Vol. 51 (12). - P. 3391-3399.

304. Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events / K. Franklin, R. J. Goldberg, F. Spencer et al. // Arch. Intern. Med. - 2004. - Vol. 164 (13). - P. 1457- 1463.

305. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a and obesity-induced insulin resistance / G. S. Hotamisligil, P. Peraldi, A. Budavari et al. // Science. - 1996. - Vol. 271. - P. 665-668. ФИО альфа и ИР

306. Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression / H. Matsui, M. Motooka, H. Koike et al. // Life Sci. - 2007. - Vol. 80. - P. 672-680.

307. Isgaard, J., Barlind, A., Johansson, I. Cardiovascular effects of ghrelin and growth hormone secretagogues / J. Isgaard, A. Barlind, I. Johansson // Cardiovasc. Hematol. Disord. Drug Targets. - 2008. - Vol. 8. - P. 133-137.

308. Ishihara, M., Kojima, S., Sakamoto, T. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era / M. Ishihara, S. Kojima, T. Sakamoto // J. Am. Heart - 2005. - Vol. 150. - P. 814-820.

309. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes / M. Y. Donath, M. Boni-Schnetzler, H. Ellingsgaard et al. // Physiology (Bethesda). - 2009 (24).-P. 325-331.

310. Jackson, M. B., Ahima, R. S. Neuroendocrine and metabolic effects of adipocyte-derived hormones / M. B. Jackson, R. S. Ahima // Clin. Sci (bond). - 2006. - HO (2). -P. 143-152.

311. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients / T. Yamazakі, J. Kishimoto, C. Ito et al. // Diabetol. Int -2011. - Vol. 2. -P. 134-140.

312. JNK and tumor necrosis factor-a mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes / M. T. Nguyen, H. Satoh, S. Favelyukis et al. // Journal of Biological Chemistry. -2005. - Vol. 280. -P. 35361-35371.

313. Jukema, J. W., van der Hoom, J. W. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy / J. W. Jukema, J. W. van der Hoom // Expert Opin on Pharmacother. - 2004. - Vol. 5. - P. 459-468.

314. Kannel, W. B., Castelli, W. P., McNamara, M. P. The coronary profile: 12- year follow-up in Framingam Study / W. B. Kannel, W. P. Castelli, M. P. McNamara // J. Occup. Med. - 1987. - Vol. 9. -P. 611-619.

315. Kaplan, N. M. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators / N. M. Kaplan // Clin. Ther. - 1996. - Vol. 18 (4). - P. 658-670.

316. Karam, J. G., Loney-Hutchinson, L., McFarlane, S. I. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by

Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators / J. G. Karam, L. Loney-Hutchinson, S. I. McFarlane // J. Cardiometab. Syndr. - 2008. - VoL 3 (I). - P. 68-69.

317. Katagiri, H., Yamada, T., Oka, Y. Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals / H. Katagiri, T. Yamada, Y. Oka // Circ Res. - 2007. - Vol. 101. - P. 27-39.

318. Katsiki, N., Banach, M. Statin use and risk of diabetes mellitus in postmenopausal women // N. Katsiki, M. Banach // Clin. Lipidol. - 2012. - Vol. 7. - P. 267-270.

319. Katsiki, N., Banach, M. Statins and the risk of diabetes: the debate / N. Katsiki, M. Banach // Arch. Intern. Med. - 2012. - Vol. 172. - P. 895-896.

320. Kershaw, E. E., Flier, J. S. Adipose tissue as an endocrine organ / E. E. Kershaw, J. S. Flier // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89 (6). - P. 2548-2556.

321. Koemer, A., Kratzsch, J., Kiess, W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come / A. Koemer, J. Kratzsch, W. Kiess // Best. Pract. Res. Clin. Endocrinol. Metab. - 2005. - Vol. 19. -525-546.

322. Koh, K. K., Sakuma, I., Quon, M. J. Differential metabolic effects of distinct statins / K. K. Koh, I. Sakuma, M. J. Quon // Atherosclerosis. - 2011. - Vol. 215. -1-8.

323. Kojima, M., Kangawa, K. Drug Insight the function of ghrelin and its potential as a multitherapeutic hormone / M. Kojima, K. Kangawa // Nature clinical practice Endocrinology and Metabolism. - 2006. - Vol. 2 (2). - P. 234-237.

324. Koltes, D., Spurlock, D. Leptin increases adipose triglyceride lipase in bovine primary adipocytes / D. Koltes, D. Spurlock // Boston Convention & Exhibition Center. - Boston. - 2013. - 156 p.

325. Kosakowski, J., Rabijewski, M., Zgliczynski, W. Ghrelin - growth hormone releasing and orexigenic hormone in men declines with age, insulin and with decrease in testosterone concentration / J. Kosakowski, M. Rabijewski, W. Zgliczynski // Neuro Endocrinol. Lett. - 2008. - Vol. 29. - P. 100-106.

326. Lam, Q. L., Lu, L.Role of leptin in immunity / Q. L. Lam, L. Lu // Cell Mol. Immunol. - 2007. - Vol. 4 (I). - P. 1-13.

327. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery / V. Haas, S. Onur, T. Paul et al. // Am. J. Clin. Nutr. -

2005. - Vol. 81 (4). - P. 889-896.

328. Leptin and coronary heart disease risk: prospective case control study of British women / D. A. Lawlor, G. Davey Smith, A. Kelly et al. // Obesity (Silver Spring). - 2007. - Vol. 15. -P. 1694-1701.

329. Leptin and coronary heart disease: prospective study and systematic review / N. Sattar, G. Wannamethee, N. Sarwar et al. // J. Am Coll. Cardiol. - 2009. - Vol. 53 (2). - P. 167-175.

330. Leptin effect on endothelial nitric oxide is mediated through Akt- endothelial nitric oxide synthase phosphorylation pathway / C. Vecchione, A. Maffei, S. Colella et al. // Diabetes. - 2002. - Vol. 51. - P. 168-173.

331. Leptin in human physiology and pathophysiology / S. M. Christos, F. Magkos, M. Brinkoetter et al. // Am J Physiol Endocrinol Metab. - 2011. - Vol. 301. - P. 567-584.

332. Leptin increase is associated with markers of the hemostatic system in obese healthy women / M. T. Guagnano, M. Romano, A. Falco et al. // J. Thromb. Haemost. - 2003. - Vol. I (I I). - P. 2330-2334.

333. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II and endothelin-1 dependent mechanisms and mediates stretch-induced hypertrophy / A. Zeidan, D. M. Purdham, V. Rajapurohitam et al. // J. Pharmacol Exp. Ther. - 2005. - Vol. 315 (3). -P. 1075-1084.

334. Leptin is associated with increased risk of myocardial infarction / S. Soderberg, B. Ahren, J. H. Jansson et al. // J. Intern. Med. - 1999. - Vol. 246. - P. 409- 418.

335. Leptin modulates the T-cell immune response and reverses starvation induced immunosuppression / G. M. Lord, G. Matarese, J. K. Howard et al. // Nature. - 1998. - Vol. 394. -P. 897-901.

336. Leptin promotes aggregation of human platelets via long form its receptor / M. Nakata, T. Yada5 N. Soejima et al. // Diabetes. - 1999. - Vol. 48. - P. 426-429.

337. Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide galanin and mediate anorexigenic leptin action / A. Laque5 Y. Zhang5

S. Gettys et al. // Am. J. Physiol. Endocrinol. Metab. - 2013. - Vol. 304 (9). - P. E999- ElOl I.

338. Leptin sensitivity in the developing rat hypothalamus / A. S. Carlo, M. Pyrski5 C. Loudes et al. // Endocrinology. - 2007. - Vol. 148 (12). - P. 6073-6082.

339. Leptin signaling in adipose tissue: role in lipid accumulation and weight gain / P. Singh5 T. E. Peterson5 F. H. Sert-Kuniyoshi et al. // Circ. Res. - 2012. - Vol. Ill (5).-P. 599-603.

340. Leptin5 not adiponectin, predicts hypertension in the Copenhagen city heart study / C. Asferg5 R. Mogelvang5 A. Flyvbjerg et al. // Am. J. Hypertens. - 2010. - Vol. 23 (3).-P. 327-333.

341. Leptinemia in persons with acute myocardial infarct / D. Stejskal5 V. Ruzicka5 J. Bartek et al. // Vnitr. Lek. - 1998. - Vol. 44. - P. 588-592.

342. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study / C. Couillard5 B. Lamarche5 P. Mauriege et al. // Diabetes Care. - 1998. - Vol. 21. - P.782-786.

343. Libby5 P., Nahrendorf5 M., Weissleder R. Molecular imaging of atherosclerosis: a progress report / P. Libby5 M. Nahrendorf5 R. Weissleder // Tex. Heart Inst. J. - 2010. - Vol. 37 (3). - P. 324-327.

344. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study / J. W. Yamell5 P. M. Sweetnam5 A. Rumley et al. // Arterioscler. Thromb. Vase. Biol. - 2000. - Vol. 20. - P. 271-279.

345. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease / V. D. de Mello5 M. Lankinen5 U. Schwab et al. // Diabetologia. - 2009. - Vol. 52 (12). - P. 2612-2615.

346. Lipids, blood pressure, kidney - what was new in 2011? / M. Barylski, J. Mayszko, J. Rysz et al. // Arch. Med. Sci. - 2011. - Vol. 7. - P. 1055-1066.

347. Lipolysis and the integrated physiology of lipid energymetabolism / S. Wang, K. G. Soni, M. Semache et al. // Molecular Genetics and Metabolism. - 2008. - Vol. 95. -P. 117-126.

348. Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-kB / D. Cai, M. Yuan, D. F. Frantz et al. // Nature Medicine. - 2005. - Vol. 11.-P. 183-190.

349. Long-term effects of central leptin and resistin on body weight, insulin resistance, and P-cell function and mass by the modulation of hypothalamic leptin and insulin signaling / S. Park, S. M. Hong, S. R. Sung et al. // Endocrinology. - 2008. - Vol. 149 (2). -P. 445-454.

350. Lopaschuk, G. D., Clifford, D. L., Folmes, C. Cardiac energy metabolism in obesity / G. D. Lopaschuk, D. L. Clifford, C.Folmes // Circulation Research. - 2007. -Vol. 101.-P. 335-347.

351. Loss of leptin actions in obesity: two concepts with cardiovascular implications / A. L. Mark, M. L. Correia, K. Rahmouni et al. // Clin. Exp. Hypertens. - 2004. - Vol. 26. -P. 629-636.

352. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity / T. F. McGuire, X. Q. Xu, S. J. Corey et al. // Biochem. Biophys. Res. Commun. - 1994. - Vol. 204. - P. 399-406.

353. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses / J. Danesh, P. Whincup, M. Walker et al. // BMJ. - 2000. - Vol. 321.-P. 199-204.

354. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes / S. M. Poykko, E. Kellokoski, S. Horkko et al. // Diabetes. - 2003. - Vol. 52. - P. 2546-2553.

355. Macrophages in human visceral adipose tissue: increase daccumulation in obesity and a source of resistin and visfatin / C. A. Curat, V. Wegner, C. Sengenes et al. // Diabetologia. - 2006. - Vol. 49. - P. 744-747.

356. Maingrette, F., Renier, G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C / F. Maingrette, G. Renier // Diabetes. - 2003. - Vol. 52 (8). - P. 2121-2128.

357. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation / F. V. Werf, J. Bax, A. Betriu et al. // Eur. Heart J. - 2008. - Vol. 29. -P. 2909-2945.

358. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) / S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al. // Diabetologia. - 2012. - Vol. 55. - P. 1577-1596.

359. Martin, S. S., Qasim, A., Reilly, M. P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease / S. S. Martin, A. Qasim, M. P. Reilly // J. Am. Coll. Cardiol. - 2008. - Vol. 52 (15). - P. 1201-1210.

360. Matsubara, M., Maruoka, S., Katayose, S. Decreased plasma adiponectin concentrations in women with dyslipidemia / M. Matsubara, S. Maruoka, S Katayose // J. Clin. Enodcrinol. Metab. - 2002. - Vol. 87 (6). - P. 2764-2769.

361. Mattu, H. S., Randeva, H. S. Role of adipokines in cardiovascular disease / H. S. Mattu, H. S. Randeva // J. Endocrinol. - 2013 - Vol. 216 (I) - P. 17-36.

362. Meams, В. M. Statins and risk of diabetes mellitus / B. M. Mearns // Nat. Rev. Cardiol. - 2012. - Vol. 9. - P. 552.

363. Mertens, I., Van Gaal, L. F. Obesity, haemostasis and the fibrinolytic system /1. Mertens, L. F Van Gaal // Obes. Rev. - 2002. - Vol. 3 (2). - P. 85-101.

364. Meta-Analysis of Impact of Different Types and Doses of Statins on New- Onset Diabetes Mellitus / E. P. Navarese, A. Buffon, F. Andreotti et al. // Am. J. Cardiol.-2013.-Vol. lll.-P. 1123-1130.

365. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study / N. Sattar, A. Gaw, O. Scherbakova et al. // Circulation. - 2003. - Vol. 108. - P. 414- 419.

366. Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states / R. Rabasa-Lhoret, J. P. Bastard, V. Jan et al. // Journal of Clinical Endocrinology and Metabolism. - 2003. - Vol. 88. - P. 4917-4923.

367. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways / M. Guha, W. Bai, J. L. Nadler et al // J Biol Chem. - 2000. - Vol. 275 (23). -P. 17728-17739.

368. Moller, D. E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes / D. E. Moller // Trends Endocrinol Metab. - 2000. - Vol. 11 (6).-P.212-217.

369. Mori, K. Kidney produces a novel acylated peptide, ghrelin / K. Mori // FEBS Lett. -2003. - Vol. 486. -P. 213-216.

370. Myocardial Fatty Acid Metabolism in Health and Disease / G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes et al // Physiol. Rev. - 2010. - Vol. 90. - P. 207-258.

371. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents / H. Tunstall-Pedoe, K. Kuulasmaa, P. Amouyel et al. // Circulation. - 1994. - Vol. 90. - P. 583-612.

372. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats / C. Berthonneche, T. Sulpice, F. Boucher et al. // Am J Physiol Heart Circ Physiol. - 2004. - Vol. 287. - P. 340-350.

373. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics / A. Wada, H. Yokoo, T. Yanagita et al. // J. Pharmacol. Sci. - 2005. - Vol. 99.-P. 128-143.

374. Newcomer, M. E., Ong, D. E. Plasma retinol binding protein: structure and function of the prototypic lipocalin / M. E. Newcomer, D. E. Ong // Biochimica et Biophysica Acta. - 2000. - Vol. 1482. - P. 57-64.

375. Newly diagnosed and previously known diabetes mellitus and I-year outcomes of acute myocardial infarction / D. Aguilar, S. D. Solomon, L. Kober et al. // Circulation. - 2004. - Vol. 110 (12). - P. 1572-1578.

376. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice / A. Trion, M. P. de Maat, J. W. Jukema et al. // Arterioscler. Thromb. Vase. Biol. - 2005. - Vol. 25. - P. 1635-1640.

377. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fe fusion protein in obese insulin- resistant patients / N. Paquot, M. J. Castillo, P. J. Lefebvre et al. // J. Clin. Endocrinol. Metab. - 2000. - Vol. 85. -P. 1316-1319.

378. Non-high-density lipoprotein cholesterol levels vs apoliprotein B or Apo B/Apo Al and risk of coronary heart disease among apparently healthy men and women / J. S. Rana, В. M. Sondermeijer, B. J. Arsenault et al. // Circulation. - 2011. - Vol. 124. -P. Al3846.

379. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study / J. F. Keaney, M. G. Larson, R. S. Vasan et al. // Arterioscler. Thromb. Vase. Biol. - 2003. - Vol. 23 (3). - P. 434-439.

380. Obesity, inflammation and acute myocardial infarction - expression of leptin, IL-6 and high sensitivity-CRP in Chennai based population / K. Rajendran, N. Devarajan, M. Ganesan et al. // Thromb. J. - 2012. - Vol. 10 (I). - P. 13.

381. Okamoto, Y., Arita, Y., Nishida, M. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls / Y. Okamoto, Y. Arita, M. Nishida // Horm Metab Res. - 2000. - Vol. 32. - P. 47-50.

382. Oliver, M. F. Sudden cardiac death: the lost fatty acid hypothesis / M. F. Oliver // Q. J. Med. - 2006. - Vol. 99 (10). - P. 701-710.

383. Oliver, M. F., Opie, L. H. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias / M. F. Oliver, L. H. Opie // Lancet. - 1994. - Vol. 343. - P.155-158.

384. Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair / M. Gwechenberger, D. Moertl, R .Pacher et al. // Croat Med J. - 2004. - Vol. 45.-P. 149-157.

385. Opie, L. H. Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia / L. H. Opie // Circulation. -

2008. - Vol. 117. - P. 2172-2177.

386. Opie, L. H., Knuuti, J. The adrenergic-fatty acid load in heat failure / L. H. Opie, J. Knuuti // J. Am. Coll. Cardiol. - 2009. - Vol. 54. - P. 1637-1646.

387. Oral, E. A., Burant, C. Leptin and insulin resistance: good, bad, or still unclear? / E. A. Oral, C. Burant // Am. J. Physiol. Endocrinol. Metab. - 2009. - Vol. 296 (2).-P. E394-E395.

388. Pair feeding-mediated changes in metabolism: stress response and pathophysiology in insulin-resistant, atherosclerosis-prone JCR: LA-cp rats / J. C. Russell, S. D. Proctor, S. E. Kelly et al. // Am. J. Physiol. Endocrinol. Metab. - 2008. - Vol. 294 (6). -P. E1078-El 087.

389. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity / Y. Arita, S. Kihara, N. Ouchi et al. // Biochem. Biophys. Res. Commun. - 1999. - Vol. 257. -P. 79-83.

390. Pedersen, B. K. IL-6 signalling in exercise and disease / В. K. Pedersen // Biochem. Soc. Trans. - 2007. - Vol. 35 (5). - P. 1295-1297.

391. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis / T. Naruko, M. Veda., S. Ehara et al. // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2006. - Vol. 26. - P.833- 877.

392. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action / V. Aguirre, E. D. Werner, J. Giraud et al. // Journal of Biological Chemistry. - 2002. - Vol. 277. - P. 1531-1537.

393. Physical activity and hemostatic and inflammatory variables in elderly men / S. G. Wannamethee, G. D. Lowe, P. H. Whincup et al. // Circulation. - 2002. - Vol. 105.-P. 1785-1790.

394. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo / J. A. Cases, I. Gabriely, X. H. Ma et al. // Diabetes. - 2001. - Vol. 50 (2). - P. 348-352.

395. Piestrzeniewicz, K., Luczak, K., Goch, H. Value of blood adipose tissue hormones concentration - adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in I-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction / K. Piestrzeniewicz, K. Luczak, H. Goch // Neuro. Endocrinol. Lett. - 2008. - Vol. 29 (4). - P. 581-588.

396. Pischon, T. Association between dietary factors and plasma adiponectin concentrations in men / T. Pischon // Am J Clin Nutr. - 2005. - Vol. 81. - P. 780-786.

397. Pittas, A. G., Joseph, N. A. Adipocytokines and insulin resistance / A. G. Pittas, N. A. Joseph // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89 (2). - P. 447-452.

398. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans / N. Stefan, B. Vozarova, T. Funahashi et al. // Diabetes. - 2002. - Vol. 51. - P. 1884-1888.

399. Plasma adiponectin levels and risk of myocardial infarction in men / T. Pischon, C. J. Girman, G. S. Hotamisligil et al. // JAMA. - 2004. - Vol. 291 (14). - P. 1730-1737.

400. Plasma concentration of a novel adipose specific protein adiponectin in type 2 diabetic patients / K. Hotta, T. Funahashi, Y. Arita et al. // Arterioscler Thromb Vase Biol. - 2000. - Vol. 20. - P.1595-1599.

401. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men / P. M. Ridker, N. Rifai, M. J. Stampfer et al. // Circulation. - 2000. - Vol. 101 (15). -P. 1767-1772.

402. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study / M. Pirro, P. Mauriege, A. Tchemof et al. // Atherosclerosis. - 2002. - Vol. 160 (2). - P. 377-384.

403. Plasma insulin, leptin and soluble TNF receptors levels in relation to obesity related atherogenic and thrombogenic cardiovascular disease risk factors among men / N. F. Chu, D. Spiegelman, G. S. Hotamisligil et al. // Atherosclerosis. - 2001. - Vol. 157 (2). -P. 495-503.

404. Plasma leptin and prognosis in patients with established coronary atherosclerosis / R. Wolk, P. Berger, R. J. Lennon et al. // J. Am Coll. Cardiol. - 2004. -Vol. 44.-P. 1819-1824.

405. Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronaiy Prevention Study (WOSCOPS) / A. M. Wallace, A. D. McMahon,

C. J. Packard et al. // Circulation. - 2001. - Vol. 104 (25). - P. 3052-3056.

406. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes / M. P. Reilly, N. Iqbal, M. Schutta et al. // J. Clin. Endocrinol. Metab. - 2004.

- Vol. 89 (8). - P. 3872-3878.

407. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm in cortisol and leptin secretion / S. R. Bomstein, J. Licinio, R. Tauchnitz et al. // J. Clin. Endocrinol. Metab. - 1998. - Vol. 83. - P. 280-283.

408. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance / J. M. Fernandez-Real, M. Broch, W. Ricart et al. // Diabetes. - 1998. -Vol. 47. -P. 1757-1762.

409. Plasma levels of the soluble fraction of tumor necrosis factor-а receptors I and 2 are independent determinants of total and LDL-cholesterol concentrations in healthy subjects / J. M. Femandez-Real, C. Gutierrez, W. Ricart et al. // Atherosclerosis.

- 1999. - Vol. 146. -P. 321-327.

410. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study /

В. Wiman, Т. Andersson, J. Hallqvist et al. // Arterioscler. Thromb. Vase. Biol. - 2000. - Vol. 20 (8).-P. 2019-2023.

411. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus / B. S. Youn5 K. Y. Yu5 H. J. Park et al. // J. Clin. Endocrinol. Metab. -2004. - Vol. 89 (I). -P. 150-156.

412. Plasma resistin levels and risk of myocardial infarction and ischemic stroke / C. Weikert5 S. Westphal5 K. Berger et al. // J. Clin. Endocrinol. Metab. - 2008. - Vol. 93 (7).-P. 2647-2653.

413. Plasma tumour necrosis factor-а and early carotid atherosclerosis in healthy middle-aged men / T. Skoog5 W. Dichtl5 S. Boquist et al. // Eur. Heart. J. - 2002. - Vol. 23.-P. 376-383.

414. Plasminogen activator inhibitor I5 transforming growth factor-betal, and BMI are closely associated in human adipose tissue during morbid obesity / M. C. Alessi5 D. Bastelica5 P. Morange et al. // Diabetes. - 2000. - Vol. 49 (8). - P. 1374- 1380.

415. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with avb3 integrin for vitronectin binding / R. Lopez-Alemany5 J. M. Redondo5 Y. Nagamine et al. // J. Eur. Biochem. - 2003. - Vol. 270. - P. 814-821.

416. Plasminogen activator inhibitor-1 modulates adipocyte differentiation / X. Liang5 T. Kanjanabuch5 S. L.Mao et al. // J. Physiol. Endocrinol. Metab. - 2006. - Vol. 290. -P. 103-113.

417. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistence and vascular risk /1. Juhan-Vague5 M. C. Alessi5 A. Mavri et al. // J. Thromb. Haemost. -2003.-Vol. l.-P. 1575- 1579.

418. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes / R. Krysiak5 A. Gdula-Dymek5 R. Bachowski et al. // Diabetes Care. - 2010. - Vol. 33 (10). - P. 2266-2270.

419. Positional cloning of the mouse obese gene and its human homologue/ Y. Zhang5 R. Proenca5 M. Maffei et al. // Nature. - 1994. - Vol. 372. - P. 425-432.

420. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/ premeal glycemia/1. Raz, A. Ceriello, P. W. Wilson et al. // Diabetes Care. - 2011. - Vol. 34. - P. 1511-1513.

421. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study / F. Cavalot, A. Pagliarino, M. Valle et al. // Diabetes Care. - 2011. - Vol. 34. - P. 2237-2243.

422. Potential role of adipocytokine leptin in acute coronary syndrome / L. Dubey, H. S. Zeng, H. J. Wang et al. // Asian. Cardiovasc. Thorac. Ann. - 2008. - Vol. 16 (2).-P. 124-128.

423. PPAR gamma ligands increase expression and plasma concentrations of adiponectin an adipose derived protein / N. Maeda, M. Takahashi, T. Funahashi et al. // Diabetes. - 2001. - Vol. 50. - P. 2094-2099.

424. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study / D. J. Freeman, J. Norrie, N. Sattar et al. // Circulation. - 2001. - Vol. 103 (3). - P. 357-362.

425. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. С-reactive protein levels and outcomes after statin therapy / P. Ridker, C. Cannon, D. Morrow et al. // N. Engl. J. Med. - 2005. - Vol. 352 (I). - P. 20-28.

426. Pre- and post-translational negative effect of b-adrenoreceptor agonists on adiponectin secretion: in vitro and in vivo studies / M. L. Delporte, T. Funahashi, M. Takahashi et al. // Biochem J. - 2002. - Vol. 367. - P. 677-685.

427. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score / A. Halkin, M. Singh, E. Nikolsky et al. // J. Am. Coll. Cardiol. - 2005. - Vol. 45 (9). - P. 1397-1405.

428. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) / К. A. Fox, O. H. Dabbous, R. J. Goldberg et al. // BMJ. - 2006. - Vol. 333 (7578).-P. 1091.

429. Predictors of hospital mortality in the Global Registry of Acute Coronary Events / С. B. Granger, R. J. Goldberg, О. M. Dabbous et. al. // Archives Internal Medicine. - 2003. - Vol. 163 (19). -P. 2345-2353.

430. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials / D. D. Waters, J. E. Ho, D. A. DeMicco et al. //J. Am. Coll. Cardiol. - 2011. - Vol. 57. -P. 1535-1545.

431. Preiss, D., Sattar, N. Statins and the risk of new-onset diabetes: a review of recent evidence / D. Preiss, N. Sattar // Curr. Opin. Lipidol. - 2011. - Vol. 22. -P. 460- 466.

432. Prevalence of conventional risk factors in patients with coronary heart disease / U. N. Khot, M. B. Khot, C. T. Bajzer et al. // JAMA. - 2003. - Vol. 290 (7). - P. 898-904.

433. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels / Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group // N. Engl. J. Med. - 1998. - Vol. 339. -P. 1349-1357.

434. Prevention of obesity and insulin resistence in mice lacking plasminogen activator inhibitor-1 / L. J. Ma, S. L. Mao, K. L. Taylor et al. // Diabetes. - 2004. - Vol. 53.-P. 336-346.

435. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study / J. R. Downs, M. Clearfield, S. Weis et al. //JAMA. - 1998. - Vol. 279 (20). -P. 1615-1622.

436. Protection from obesity-induced insulin resistance in mice lacking TNF-a function / K. T. Uysal, S. M. Wiesbrock, M. W. Marino et al. // Nature. - 1997. - Vol. 389.-P.610-614.

437. Protein phosphatase I (PP-I) dependent inhibition of insulin secretion by leptin in INS-1 pancreatic cells and human pancreatic islets / P. Kuehnen, K. Laubner, K. Raile et al. // Endocrinology. - 2011. - Vol. 152 (5). -P. 1800-1808.

438. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans / A. Katz, S. Nambi, K. Mather et al. // J. Clin. Endocrinol. Metab. -2000. - Vol. 85. -P. 2402-2410.

439. QUICKI Is Useful for Following Improvements in Insulin Sensitivity after Therapy in Patients with Type 2 Diabetes Mellitus / A. Katsuki, S.Yasuhiro, C. G. Esteban et al. // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87. - P. 2906-2908.

440. Race and gender differences in C-reactive protein levels / A. Khera, D. K. McGuire, S. A. Murphy et al. // J. Am. Coll. Cardiol. - 2005. - Vol. 46. - P. 464-469.

441. Rajapurohitam V., Javadov S. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1 / V. Rajapurohitam, S. Javadov // J. Mol. Cell. Cardiol. - 2006. - Vol. 41 (2). - P. 74-265.

442. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) / T. R. Pedersen, J. Kjekshus, K. Berg et al. // Atheroscler. Suppl. - 2004. - Vol. 5 (3). - P. 81-87.

443. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at I year / K. Malmberg, L. Ryden, S. Efendic et al. // J. Am Coll. Cardiol. - 1995. - Vol. 26. -P. 57-65.

444. Rat heart is a site of leptin production and action / D. M. Purdham, M. X. Zou, V. Rajapurohitam et al. // Am. J. Physiol. Heart Circ. Physiol. - 2004. - Vol. 287. -P. H2877-H2884.

445. Ray, K. K., Cannon, С. P. The potential relevance of the multiple lipid- independent (pleiotropic) effects of statins in the management of acute coronary syndromes / K. K. Ray, С. P. Cannon // J. Am. Coll. Cardiol. - 2005. - Vol. 46 (8). - P. 1425-1433.

446. RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes / C. Erikstmp, 0. H. Mortensen, A. R. Nielsen et al. // Diabetes, Obesity & Metabolism. - 2009. - Vol. 11. -P. 204-212.

447. Reaven, G. M. Role of insulin resistance in human disease (syndrome X): an expanded definition / G. M. Reaven // Annu Rev. Med. - 1993. - Vol. 44. - P. 121- 131.

448. Recombinant leptin promotes atherosclerosis and thrombosis inapolipoprotein E-defi cient mice / P. F. Bodary, S. Gu, Y. Shen et al. // Arterioscler. Thromb. Vase. Biol. - 2005. - Vol. 25. - P. 119-122.

449. Reduced tyrosine kinase activity of the insulin receptor in obesitydiabetes /

G. S. Hotamisligil, A. Budavari, D. Murray et al. // J. Clin. Invest. - 1994. - Vol. 94. - P. 1543-1549.

450. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial / P. M. Ridker, E. Danielson, F. A. Fonseca et al. // Lancet. - 2009. - Vol. 373 (9670). - P. 1175-1182.

451. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients / H. Mabuchi, T. Higashikata, M. Kawasliiri et al. // J. Atheroscler. Thromb. -2005. - Vol. 12 (2). -P. 111-119.

452. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans / J. M. Bruun, A. S. Lihn, C. Verdich et al. // Am J. Physiol. Endocrinol. Metab. -2003. - Vol. 285 (3). -P. E527-E533.

453. Regulation of fasted blood glucose by resistin / R. R. Banerjee, S. M. Rangwala, J. S. Shapiro et al. // Science. - 2004. - Vol. 303 (5661). - P. 1195-1198.

454. Relation between retinol, retinolbinding protein 4, transthyretin and carotid intima media thickness / T. Bobbert, J. Raila, F. Schwarz et al. // Atherosclerosis. - 2010.-Vol. 213.-P. 549-551.

455. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population / J. Sierra-Johnson, A. Romero- Corral, F. Lopez-Jimenez et al. // Am. J. Cardiol. - 2007. - Vol. 100 (2). - P. 234-239.

456. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients / T. Skurk, V. van Harmelen, Y. M. Lee et al. // Horm. Metab. Res. - 2002. - Vol. 34 (11-12). - P. 659-663.

457. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes / P. Calabro, D. Chang, J. T. Willerson et al. // J. Am Coll. Cardiol. - 2005. - Vol. 46. -P. 1112-1113.

458. Ren, J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function / J. Ren // J. Endocrinol. - 2004. - Vol. 181. - P. 1-10.

459. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia / reperfusion / N. G. Frangogiannis, M. L. Lindsey, L. H. Michael et al. // Circulation. - 1998. - Vol. 7. - P. 699-710.

460. Residual beta cell function in newly diagnosed type I diabetes after treatment with atorvastatin: the Randomized DIATOR Trial / S. Martin, C. Herder, N.

C. Schloot et al. // PLoS One. - 2011. - Vol. 6. - P. ЄІ7554.

461. Resistin is an inflammatory marker of atherosclerosis in humans / M. P. Reilly, M. Lehrke, M. L. Wolfe et al. // Circulation. - 2005. - Vol. Ill (7). - P. 932- 939.

462. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis / H. S. Jung, К. H. Park, Y. M. Cho et al. // Cardiovasc. Res. - 2006. - Vol. 69(1).-P. 76-85.

463. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction / S. Verma, S. H. Li, C. H. Wang et al. // Circulation. - 2003. - Vol. 108 (6). - P. 736-740.

464. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity / J. Vendrell, M. Broch, N. Vilarrasa et al. // Obes. Res. - 2004. -Vol. 12 (6).-P. 962-971.

465. Resistin, an adipokine with potent proinflammatory properties / M. Bokarewa, I. Nagaev, L. Dahlberg et al. // J. Immunol. - 2005. - Vol. 174 (9). - P. 5789-5795.

466. Retinol binding protein 4, low birth weight-related insulin resistance and hormonal contraception / A. Zugaro, C. Pandolfi, A. Barbonetti et al. // Endocrine. - 2007.-Vol. 32.-R 166-169.

467. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women / Z. Mallat, T. Simon, J. Benessiano et al. // Journal of Clinical Endocrinology and Metabolism. - 2009. - Vol. 94. - P. 255-260.

468. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkb / M. Yuan, N. Konstantopoulos, J. Lee et al. // Science. - 2001. - Vol. 293. -P. 1673-1677.

469. Review: leptin gene expression in the placenta - regulation of a keyhormone in trophoblast proliferation and survival / J. L. Maymo, A. P. Perez, Y. Gambino et al. // Placenta. - 2011. - Vol. 32 (2). - P. S146-S153.

470. Ridker, P. M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention / P. M. Ridker // Circulation. - 2003. - Vol. 107 (3). - P. 363-369.

471. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis / D. Preiss, S. R. Seshasai, P. Welsh et al. // JAMA. - 2011. - Vol. 305. - P. 2556-2564.

472. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide / P. A. Kavsak, D. T. Ко, A. M. Newman et al. // Clinical Chemistry. - 2007. - Vol. 53 (12).-P.2112-2118.

473. Rizzo, M., Bemeis, K. Low-density lipoprotein size and cardiovascular risk assessment / M. Rizzo, K. Berneis // QJM. - 2006. - Vol. 99. - P. 1-14.

474. Role of baseline leptin and ghrelin levels on body weight and fat mass changes after an energy-restricted diet intervention in obese women: effects on energy metabolism /1. Labayen, F. B. Ortega, J. R. Ruiz et al. // J. Clin. Endocrinol. Metab. - 2011. - Vol. 96 (6). -P. E996-E1000.

475. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? / K. Reifenberg, H. A. Lehr, D. Baskal et al. // Arterioscler. Thromb. Vase. Biol. -2005. - Vol. 25. -P. 1641-1646.

476. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain / S. E. Kahn, S. M. Haffner, G. Viberti et al. // Diabetes Care. - 2010. - Vol. 33. - P. 177-183.

477. Rosuvastatin in older patients with systolic heart failure / J. Kjekshus, E. Apetrei, V. Barrios et al. // N. Engl. J. Med. - 2007. - Vol. 357. - P. 2248-2261.

478. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein / P. M. Ridker, E. Danielson, F. A. Fonseca et al. / N. Engl. J. Med. - 2008. - Vol. 359. -P. 2195-2207.

479. Sack, M. N., Smith, R. M., Opie, L. H. Tumor necrosis factor in myocardial hypertrophy and ischaemia - an anti-apoptotic perspective / M. N. Sack, R. M. Smith, L. H. Opie // Cardiovasc. Res. - 2000. - Vol. 3. - P. 688-695.

480. Sampson, U. K., Linton, M. F., Fazio, S. Are statins diabetogenic? / U. K. Sampson, M. F. Linton, S. Fazio // Curr. Opin. Cardiol. - 2011. - Vol. 26 (4). - P. 342- 347.

481. Sattar, N., Taskinen, M. R. Statins are diabetogenic - myth or reality? / N. Sattar, M. R. Taskinen // Atheroscler. Suppl. - 2012. - Vol. 13. - P. 1-10.

482. Sell, H., Eckel, J. Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-alpha / H. Sell, J. Eckel // Diabetologia. - 2007. - Vol. 50. -P. 2221-2223.

483. Serine phosphorylation of insulin receptor substrate I by inhibitor кВ kinase complex / Z. Gao, D. Hwang, F. Bataille et al. // Journal of Biological Chemistry. - 2002. - Vol. 211.-V. 48115-48121.

484. Serum leptin and myocardial infarction in hypertension / S. M. Wallerstedt, A. L. Eriksson, A. Niklason et al. // Blood Press. - 2004. - Vol. 13 (4). - P. 243-246.

485. Serum resistin concentrations and risk of new onset heart failure in older persons: the Health, Aging and Body Composition (Health ABC) Study / J. Butler, A.

Kalogeropoulos, V. Georgiopoulou et al. // Harris for the Health ABC Study. Arterioscler. Thromb. Vase. Biol. -2009. - Vol. 29 (7). -P. 1144-1149.

486. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes / Q. Yang, T. E. Graham, N. Mody et al. // Nature. - 2005. - Vol. 436. -P. 356-362.

487. Seth, S. M., Atif, Q., Muredach, P. R. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease / S. M. Seth, Q. Atif, P. R. Muredach // J. Am. Coll. Cardiol. - 2008. - Vol. 52 (15). - P. 1201-1210.

488. Seufert, J. Leptin effects on pancreatic p-cell gene expression and function / J. Seufert // Diabetes. - 2004. - Vol. 53 (I). - P. 152-158.

489. Shankar, A., Xiao, J. Positive relationship between plasma leptin level and hypertension / A. Shankar, J. Xiao // Hypertension. - 2010. - Vol. 56 (4). - P. 623-628.

490. Sherwin, R., Jastreboff, A. M. Year in diabetes 2012: The diabetes tsunami / R. Sherwin, A. M. Jastreboff // J. Clin. Endocrinol. Metab. - 2012. - Vol. 97. - P. 4293-4301.

491. Sidhu, J. S., Cowan, D., Kaski, J. C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, Creactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients / J. S. Sidhu, D. Cowan, J. C. Kaski // J. Am. Coll. Cardiol. - 2003. - Vol. 42.-P. 1757-1763.

492. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin / L. Li, J. C. Mamputu, N. Wiemsperger et al. // Diabetes. - 2005. - Vol. 54. - P. 2227-2234.

493. Significance of an index of insulin resistance in non-diabetic patients with impaired fasting glucose with acute myocardial infarction and its correlation to short term outcome / D. P. Sinha, S. Ahmed, A. K. Baneeijee et al. // Indian Heart J. - 2009. -Vol. 61 (I).-P. 40-43.

494. Significance of an index of insulin resistance on admission in non-diabetic patients with acute coronary syndromes // P. J. Stubbs, J. Alaghband-Zadeh, J. F. Laycock et at. // Heart. - 1999. - Vol. 82. - P. 443-447.

495. Simsek, S., Schalkwijk, C. G., Wolffenbuttel, В. H. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes - the CORALL study / S. Simsek, C. G. Schalkwijk, B. H. Wolffenbuttel // Diabet. Med. - 2012. - Vol. 29. - P. 628-631.

496. SOCS-I and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRSl and IRS2 / L. Rui, M. Yuan, D. Frantz et al. // Journal of Biological Chemistry. - 2002. - Vol. 277. - P. 42394-42398.

497. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-a in the adipose tissue of obese mice / Emanuelli B., Peraldi P., Filloux C. et al. // Journal of Biological Chemistry. - 2001. - Vol. 276. - P. 47944-47949.

498. Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction / Y. Monden, T. Kubota,

T. Tsutsumi et al. // Cardiovasc Res. - 2007. - Vol. 73. - P. 794-805.

499. Soluble TNFa receptors in young obese subjects with normal and impaired glucose tolerance / S. Dzienis-Straczkowska, M. Straczkowski, M. Szelachowska et al. // Diabetes Care. - 2003. - Vol. 26. - P. 875-880.

500. Staiger, H., Tschritter, O., Kausch, C. Human serum adiponectin levels are not under shot-term negative control by free fatty acids in vivo / H. Staiger, O. Tschritter, C. Kausch// Horm. Metab. Res. - 2002. - Vol. 34. -P. 601-603.

501. Statin discontinuation: counterbalancing the benefits with the potential risks / K. I. Paraskevas, S. Koupidis, F. Gentimi et al. // Arch. Med. Sci. - 2011. - Vol. 7. - P. 1076-1077.

502. Statin Therapy and New-Onset Diabetes: Molecular Mechanisms and Clinical Relevance / M. Banach, M. Malodobra-Mazur, A. Gluba et al. // Curr. Pharm. Des. - 2013. - Vol. 19 (27). - P. 4904-4912.

503. Statin therapy and risk of developing type 2 diabetes: a meta-analysis / S. N. Rajpathak, D. J. Kumbhani, J. Crandall et al. // Diabetes Care. - 2009. - Vol. 32 (10).-P. 1924-1929.

504. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? / Y. Ma, A. Culver, J. Rossouw et al. // Ther. Adv. Cardiovasc. Dis. -2013.-Vol. 7.-P.41-44.

505. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative / A. L. Culver, I. S. Ockene, R. Balasubramanian et al. // Arch. Intern. Med. - 2012. - Vol. 172. - P. 144-152.

506. Statins and New-Onset Diabetes / M. Barylski, D. Nikolic, M. Banach et al. // Current Pharmaceutical Design. - 2013. - Vol. 19. - P. 1-8.

507. Statins and new-onset diabetes: a retrospective longitudinal cohort study / T. Ma, L. Tien, C. L. Fang et al. // Clin. Ther. - 2012. - Vol. 34. - P. 1977-1983.

508. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials / N. Sattar, D. Preiss, H. M. Murray et al. // Lancet. - 2010. - Vol. 375. -735-742.

509. Statins, risk of diabetes, and implications on outcomes in the general population / K. L. Wang, C. J. Liu, T. F. Chao et al. // J. Am. Coll. Cardiol. - 2012. - Vol. 60.-P. 1231-1238.

510. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial) / P. H. Jones, M. H. Davidson, E. A. Stein et al. // Am. J. Cardiol. - 2003. - Vol. 92 (2) - P. 152-160.

511. Steppan, C. M., Lazar, M. A. Resistin and obesity-associated insulin resistance / С. M. Steppan, M. A. Lazar // Trends in Endocrinology and Metabolism. -

2002. -Vol. 13(1).-P. 18-25.

512. Sundell, J. Obesity and diabetes as risk factors for coronary artery disease: from the epidemiological aspect to the initial vascular mechanisms / J. Sundell // Diabetes Obes. Metab. - 2005. - Vol. 7. - P. 9-20.

513. Synthetic peroxisome proliferator-activated receptorgamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients / W. S. Yang, C. Y. Jeng, T. J. Wu et al. // Diabetes Care. - 2002. - Vol. 25. - P. 376-380.

514. Taegtmeyer, H., McNulty, P., Young, M. E. Adaptation and Maladaptation of the Heart in Diabetes: Part I, General Concepts / H. Taegtmeyer, P. McNulty, M. E. Young // Circulation. - 2002. - Vol. 105. - P.1727-1733

515. Takaya, K. Ghrelin strongly stimulates growth hormone release in humans / K. Takaya // J. Clin. Endocrinol. Metab. - 2000. - Vol. 85. - P. 4908-4911.

516. Tansey, M. J., Opie, L. H. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction / M. J. Tansey, L. H. Opie // Lancet. - 1983. - Vol. 23 (8347). - P. 419-422.

517. Tenenbaum, A., Fisman, E. Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? / A. Tenenbaum, E. Z. Fisman // Cardiovasc. Diabetol. - 2012. - Vol. 11. - P. 140.

518. Teramoto, T. Pitavastatin: clinical effects from the LIVES Study / T. Teramoto // Atheroscler. Suppl. - 2011. - Vol. 12. - P. 285-2258.

519. Testosteron administration suppresses adiponectin levels in men / S. T. Page, K. L. Herbst, J. K. Amory et al. // J Androl. - 2005. - Vol. 26. - P. 85-92.

520. The association of intensive statin therapy on long-term risks of cardiovascular events and diabetes following acute myocardial infarction (abstract) / A. Yousef, J. V. Tu, J. Wang et al. // Circulation. - 2012. - Vol. 125. - P. e859.

521. The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? // Diabetes Care. - 2003. - Vol. 26. - P. 688-696.

522. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia / Diabetes Atorvastin Lipid Intervention (DALI) Study Group // Diabetes Care. - 2001. - Vol. 24 (8). - P. 1335-1341.

523. The effect of early, intensive statin therapy on acute coronary syndrome /

E. Hulten, J. L. Jackson, K. Douglas et al. // Arch. Intern. Med. - 2006 - Vol. 166 (17). -P. 1814-1821.

524. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetes subjects / J. G. Yu, S. Javorschi, A. L. Hevener et al. // Diabetes. - 2002. - Vol. 51. - P. 2968-2974.

525. The emerging role of ITOL in glucose metabolism / B. G. Drew, K. A. Rye, S. J Duffy et al. // Nat. Rev. Endocrinol. - 2012. - Vol. 8. - P. 237-245.

526. The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity / T. Yamauchi, J. Kamon, H. Waki et al. // Nat Med. -2001.-Vol. 7. -P. 941-946.

527. The hormone resistin links obesity to diabetes / C. M. Steppan, S. T. Bailey, S. Bhat et al. // Nature. - 2001. - Vol. 409. - P. 307-312.

528. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy / A. Bielecka-Dabrowa, J.

H. Goch, D. P. Mikhailidis et al. // Med. Sci. Monit. - 2009. - Vol. 15 (12). - P. MS12- MS23.

529. The kidney as a second site of human C-reactive protein formation in vivo / W. J. Jabs, B. A. Logering, P. Gerke et al. // Eur J Immunol. - 2003. - Vol. 33. - P. 152-161.

530. The Plasminogen Activator Inhibitor-1 -675 4G/5G genotype influences the risk of Myocardial Infarction associated with elevated plasma proinsulin/insulin levels in men from Europe /1. Juhan-Vague, P. E. Morange, C. Frere et al. // J. Thromb. Haemost. - 2003. - Vol. I. - P. 2322-2329.

531. The roles of IL-6, IL-10 and IL-IRA in obesity and insulin resistance in African-Americans / B. A. Charles, A. Doumatey, H. Huang et al. // J. Clin. Endocrinol. Metab. -2011. - Vol. 96 (12). -P. E2018-E2022.

532. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) / С. B. Newman, M. Szarek, H. M. Colhoun et al. // Diab. Vase. Dis. Res. - 2008. - Vol. 5. - P. 177-183.

533. Time for new indications for statins? / M. Banach, D. P. Mikhailidis, S. E. Kjeldsen et al. // Med. Sci. Monit. - 2009. - Vol. 15. - P. MSI- MS5.

534. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction / A. C. Sposito, S. N. Santos, E. C. de Faria et al. // Coelho. Arterioscler. Thromb. Vase. Biol. - 2011. - Vol. 31 (5). - P.1240-1246.

535. TNF-a up-regulates protein level and cell surface expression of the leptin receptor by stimulating its export via a PKC-dependent mechanism / L. Gan, K. Guo, M. L. Cremona et al. // Endocrinology. - 2012. - Vol. 153. - P. 5821-5833.

536. Tobacco modalities used and outcome in patients with acute coronary syndrome: an observational report / J. Al Suwaidi, K. Al Habib, R. Singh et al. // Postgrad. Med. J. - 2012. - Vol. 88 (1044). - P. 566-574.

537. Tokuyama, Y., Osawa, H., Ishizuka, T. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus / Y. Tokuyama, H. Osawa, T. Ishizuka// Metabolism. - 2007. - Vol. 56 (5). - P. 693-698.

538. Tomkin, G. H. Atherosclerosis, diabetes and lipoproteins / G. H. Tomkin // Expert. Rev. Cardiovasc. Ther. - 2010. - Vol. 8 (7). - P. 1015-1029.

539. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women / C. Heidemann, Q. Sun, R. M. van Dam et al. // Ann. Intern. Med. - 2008. - Vol. 149 (5). - P. 307-316.

540. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice / G. M. Hirschfield, J. R. Gallimore, M. C. Kahan et al. // Proc. Natl. Acad. Sci U S A. - 2005. - Vol. 102. - P. 8309-8314.

541. Trayhum, P., Wood, I. S. Signalling role of adipose tissue: adipokines and inflammation in obesity / P. Trayhum, I. S. Wood // Biochemical Society Transactions. -2005.-Vol. 33 (5).-P. 1078-1081.

542. Treating to target patients with primary hyper! ipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) / H. J. Milionis, E. Rizos, M. Kostapanos et al. // Curr. Med. Res. Opin - 2006. - Vol. 22. - P. 1123-1131.

543. Tumor necrosis factor a inhibits signaling from the insulin receptor / G. S. Hotamisligil, D. L. Murray, L. N. Choy et al. // PNAS. - 1994. - Vol. 91. - P. 4854- 4858.

544. Tumor necrosis factor-alpha contributes to ischemia- and reperfusion- induced endothelial activation in isolated hearts / C. Kupatt, H. Habazettl, A. Goedecke et al. // Circ. Res. - 1999. - Vol. 4. - P. 392-400.

545. Two prospective studies found that elevated 2-hr glucose predictedmale mortality independent of fasting glucose and HbAlc / Q. Qiao, J. M. Dekker, F. de Vegt et al. // J. Clin. Epidemiol. - 2004. - Vol. 57. - P. 590-596.

546. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention / A. Badawi, A. Klip, P. Haddad et al. // Diabetes Metab. Syndr. Obes. - 2010. - Vol. 3. -P. 173-186.

547. Unger, R. H. Hyperleptinemia: protecting the heart from lipid overload / R. H. Unger // Hypertension. - 2005. - Vol. 45. -1031-1034.

548. Uysal, K. T., Wiesbrock, S. M., Hotamisligil, G. S. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-a - mediated insulin resistance in genetic obesity / К. T. Uysal, S. M. Wiesbrock, G. S. Hotamisligil // Endocrinology. - 1998. - Vol. 139. -P. 4832-4838.

549. VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes / W. Duckworth, C. Abraira, T. Moritz New England Journal of Medicine. - 2009. - Vol. 360 (2). - P. 129-139.

550. Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp / F. A. Moura, L. S. Carvalho, R. M. Cintra et al. // Am J Physiol Endocrinol Metab. - 2014. - Vol. 306 (4).-P. E399- E403.

551. Vaughan, D. E. PAI-I and atherothrombosis / D. E. Vaughan // J. Thromb. Haemost. - 2005. - Vol. 3 (8). -P. 1879-1883.

552. Verma, S., Yeh, E. T. C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation / S. Verma, E. T. Yeh // Am. J. Physio.I Regul. Integr. Comp. Physiol. - 2003. - Vol. 285. - P. R1253-R1256.

553. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women / J. W. Lee, J. A. Im, H. R. Lee et al. // Obesity. - 2007. - Vol. 15. - P. 2225-2232.

554. Von Willebrand factor and coronary heart disease: prospective study and meta-analysis / P. H. Whincup, J. Danesh, M. Walker et al. // Eur. Heart. J. - 2002. - Vol. 23.-P. 1764-1770.

555. Wallace, T. M., Levy, J. C., Matthews, D. R. Use and abuse of HOMA modeling / T. M. Wallace, J. C. Levy, D. R. Matthews // Diabetes Care. - 2004. - Vol. 27 (6).-P. 1487-1495.

556. Wallander, M., Soderberg, S., Norhammar, A. Leptin: a predictor of abnormal glucose toleranceand prognosis in patients with myocardial infarction and without previously known Type 2 diabetes / M. Wallander, S. Soderberg, A. Norhammar // Diabet Med. - 2008. - Vol. 25 (8). - P. 949-955.

557. Wanders, D., Plaisance, E. P., Judd, R. L. Pharmacological effects of lipidlowering drugs on circulating adipokines / D. Wanders, E. P. Plaisance, R. L. Judd // World J. Diabetes. -2010. - Vol. I. -P. 116-128.

558. Wang, B., Jenkins, J. R., Trayhum, P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-a / B. Wang, J. R. Jenkins, P. Trayhurn // Am J Physiol Endocrinol Metab. - 2005. - Vol. 288. - P. E731-E740.

559. Wang, Z., Hoy, W. E. C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians / Z. Wang, W. E. Hoy // Diabetes Res. Clin. Pract. - 2007.-Vol. 76(1).-P. 37-43.

560. Watts, G. F., Ooi, E. M. Balancing the cardiometabolic benefits and risks of statins / G. F. Watts, E. M. Ooi // Lancet. - 2012. - Vol. 380. - P. 541-543.

561. Woods, J. A., Vieira, V. J., Keylock, T. K. Exercise, Inflammation, and Innate Immunity / J. A. Woods, V. J. Vieira, T. K. Keylock // Neurologic Clinics. -

2006. - Vol. 24 (3). - P. 585-599.

562. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects // DoH. - 2008. - P. 1-5.

563. Yamagishi, S., Imaizumi, T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy / S. Yamagishi, T. Imaizumi // Curr. Pharm. Des. - 2005. - Vol. 11 (18). - P. 2279-2299.

564. Yang, R., Barouch, L. A. Leptin signaling and obesity. Cardiovascular consequences / R. Yang, L. A. Barouch // Circulation Research. - 2007. - Vol. 101. - P. 545-559.

565. Yeh, E. T. A new perspective on the biology of C-reactive protein / E. T. Yeh // Circulation Res. - 2005. - Vol. 97. - P. 609-611.

566. Yusuf, S. INTER-HEART: a study of risk factors for first myocardial infarction in 52 countries and over 27000 subjects / S. Yusuf // Paper presented at the European Society for Cardiology Congress. - 2004. - Munich, Germany. - URL: www.cardiosourse.com (10.11.2012).

567. Zaharan, N. L., Williams, D., Bennett, K. Statins and Risk of Treated Incident Diabetes in a Primary Care Population / N. L. Zaharan, D. Williams, K. Bennett//Br. J. Clin. Pharmacol. -2013. - Vol. 75(4). P. 1118-1124.

<< |
Источник: Груздева Ольга Викторовна. ИНСУЛИНОРЕЗИСТЕНТНОСТЬ ПРИ ИНФАРКТЕ МИОКАРДА: КЛИНИКО-ПАТОФИЗИОЛОГИЧЕСКИЕ ЗАКОНОМЕРНОСТИ, ПОДХОДЫ К ОПТИМИЗАЦИИ РАННЕЙ ДИАГНОСТИКИ И ТЕРАПИИ СТАТИНАМИ. 2014

Еще по теме СПИСОК ЛИТЕРАТУРЫ:

  1. СПИСОК ЛИТЕРАТУРЫ
  2. СПИСОК ЛИТЕРАТУРЫ
  3. СПИСОК ЛИТЕРАТУРЫ
  4. Список литературы
  5. Список литературы
  6. СПИСОК ЛИТЕРАТУРЫ
  7. СПИСОК ЛИТЕРАТУРЫ
  8. СПИСОК ЛИТЕРАТУРЫ
  9. СПИСОК ЛИТЕРАТУРЫ
  10. Список литературы
  11. СПИСОК ЛИТЕРАТУРЫ
  12. СПИСОК ЛИТЕРАТУРЫ
  13. СПИСОК ЛИТЕРАТУРЫ
  14. СПИСОК ЛИТЕРАТУРЫ
  15. СПИСОК ЛИТЕРАТУРЫ
  16. СПИСОК ЛИТЕРАТУРЫ
  17. СПИСОК ЛИТЕРАТУРЫ
  18. СПИСОК ЛИТЕРАТУРЫ
  19. Список литературы
  20. СПИСОК ЛИТЕРАТУРЫ
- Акушерство и гинекология - Анатомия - Андрология - Биология - Болезни уха, горла и носа - Валеология - Ветеринария - Внутренние болезни - Военно-полевая медицина - Восстановительная медицина - Гастроэнтерология и гепатология - Гематология - Геронтология, гериатрия - Гигиена и санэпидконтроль - Дерматология - Диетология - Здравоохранение - Иммунология и аллергология - Интенсивная терапия, анестезиология и реанимация - Инфекционные заболевания - Информационные технологии в медицине - История медицины - Кардиология - Клинические методы диагностики - Кожные и венерические болезни - Комплементарная медицина - Лучевая диагностика, лучевая терапия - Маммология - Медицина катастроф - Медицинская паразитология - Медицинская этика - Медицинские приборы - Медицинское право - Наследственные болезни - Неврология и нейрохирургия - Нефрология - Онкология - Организация системы здравоохранения - Оториноларингология - Офтальмология - Патофизиология - Педиатрия - Приборы медицинского назначения - Психиатрия - Психология - Пульмонология - Стоматология - Судебная медицина - Токсикология - Травматология - Фармакология и фармацевтика - Физиология - Фтизиатрия - Хирургия - Эмбриология и гистология - Эпидемиология -